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Abstract 
Iron is not a trace e1ement in mammalian physiology. Using textbook values for 
blood volume (5.5 L), red blood cell (RBC) count (5 million/ilL), and a lifespan of 120 
days for red blood cells, the equilibrium value forthe erythrocyte generation/death rate in 
the average adult male human is over 2 million/sec. It follows that the amount of iron 
required for hemoglobin synthesis in one day amounts to about 25 mg. Virtually every 
atom ofthat 25 mg is recyc1ed by macrophages of the reticuloendothelial system (RES) 
that provide iron to the plasma for its subsequent delivery back to the erythron (with a 
small fraction going to other tissues). In light of the certain toxicity of unprotected iron, 
both erythroid precursors and RES macrophages perform remarkable tasks in handling 
such copious amounts of the catalytic metal. In my studies, l have examined specific 
aspects of iron metabolism in these two tissues. 
Iron is taken up by nearly every cell through a mechanism of receptor-mediated 
endocytosis, whereby the plasma iron binding protein transferri~ (Tt) binds to its cognate 
receptor (TiR) on the ceU surface, followed by intemalization ofthe complex into a 
membrane bound organelle. Subsequent to endocytosis, the endosome is acidified by a 
v-ATPase proton pump, facilitating the release ofiron from Tf. Through an unknown 
mechanism, iron is targeted to the inner membrane of the mitochondria, where the 
enzyme that inserts Fe2+ into protoporphyrin IX, ferroche1atase, resides. Although it has 
been demonstrated that the divalent metal transporter, DMTl, is responsible for the 
egress ofreduced Fe from the vesicle, the immediate fate of the iron atoms after their 
transport across the vesicular membrane remains unknown. Therefore, we have 
investigated the uptake of iron in reticulocytes, ceUs that are taking up large amounts of 
11 
iron for the synthesis ofhemoglobin. Through both biochemical and imaging techniques, 
we have demonstrated that iron is transferred via a direct interorganellar relation between 
the endosome and mitochondria. 
The "haemoglobin-deficit" (hbd) mouse has an erythroid-specific mutation which 
is responsible for its microcytic, hypochromic phenotype. Previous studies have shown 
that these mice have normal dietary iron acquisition and normal to elevated serum iron 
leve1s. We therefore investigated the handling of iron in reticulocytes from these animaIs 
to determine whether the mutated gene possibly plays a role in the trafficking of 
transferrin-iron-containing organelles. A systematic examination ofthe steps in the 
transferrin pathway revealed that the intracellular trafficking of the protein is 
compromised in the hbd mice. 
The rapid turnover of iron by macrophages of the RES requires heme oxygenase-
1 (HO-l), which catalyzes the rate-limiting step in herne degradation. This highly 
inducible enzyme, besides its major role in erythrocyte iron recyc1ing, has been 
dernonstrated to confer astonishing cytoprotectivity to cells and tissues in which its 
expression is e1evated (either through chemical induction or genetic manipulation). In 
addition to, reportedly protective, carbon monoxide and biliverdin, the HO-l catalyzed 
reaction re1eases ferrous iron, which itse1f is a potent pro-oxidant. Also, it is unlikely that 
there exists a significant amount offree heme in most tissues (i.e., non-erythroid, non- . 
erythrophagocytic), to provide significant amounts of substrate to this enzyme. Hence, it 
is ternpting to speculate that the mechanism ofheme oxygenase cytoprotection is 
removed from its function ofherne catabolism. Therefore, we investigated whether 
increased expression ofherne oxygenase will, in and of itself, alter iron metabolism in 
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cultured ceUs. My experiments show that in the absence of exogenous hemin, elevation 
of HO-I protein levels does not have any effect on cellular iron metabolism in cultured 
ceUs. 
IV 
Résumé 
Le fer n'est pas un élément peu abondant dans la physiologie des mammifères. Si 
on consulte la littérature, pour un volume de 5.5 1, un nombre de globules rouges de 5 
millionS/ill et une durée de vie de 120 jours, la valeur d'équilibre du cycle 
génération/mortalité des érythrocytes chez un adulte, humain, mâle, est de plus de 2 
millions par seconde. Il en résulte que la quantité de fer requis pour la synthèse 
d'hémoglobine durant une journée est d'à peu prés 25 mg. Pratiquement chaque atome 
faisant partie des ces 25 mg est recyclé par les macrophages du système réticulo-
endothélial (RES), responsable d'approvisionner le plasma en fer pour qu'il puisse être 
en suite rendu à l'érythrone (un petite partie du fer est délivrée aux autres tissus). Si on 
tient compte du fait que le fer libre est certainement toxique, les précurseurs érythroïdes 
et les macrophages RES font un travail remarquable en gérant d'aussi larges quantités de 
ce métal catalytique. l'ai consacré mes études, à examiner les aspects spécifiques du 
métabolisme du fer dans ces deux tissus. 
Le fer est absorbé par pratiquement chaque cellule par un mécanisme 
d'endocytose récepteur-dependent. La transferrine (Tf), protéine de transport du fer dans 
le plasma, lie le fer à son récepteur apparenté (TfR) localisé à la surface de la cellule. Il 
s'en suit une internalisation du complexe, ce qui résulte en une organelle attachée à la 
membrane. Après t'endocytose, l'endosome est acidifié par une pompe de proton de v-
A TPase, facilitant le dégagement du fer de la Tf. 
Par un mécanisme inconnu, le fer est transporté vers la membrane intérieure des 
mitochondries, où réside l'enzyme, ferrochelatase, qui insère Fe2+ dans la 
protoporphyrine IX. Bien qu'il ait été démontré que le transporteur de métaux divalents, 
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DMTI, soit responsable de la sortie de la forme réduite du fer de la vésicule, le destin 
immédiat des atomes de fer après leur transport à travers la membrane vésiculaire 
demeure inconnu. Par conséquent, nous avons étudié la prise du fer dans les 
réticulocytes, cellules qui consomment de grandes quantités de fer pour la synthèse de 
l'hémoglobine. En utilisant des techniques biochimiques et d'analyse d'image, nous 
avons démontré que le fer est transféré via des connections directes inter-organes entre 
les endosomes et les mitochondries. 
Les souris qui ont une «déficience d'hémoglobine» (hbd) présentent une 
mutation spécifique des érythrocytes qui est responsable d'un phénotype microcytique et 
hypochromique. Les études précédentes ont prouvé que ces souris absorbent 
normalement le fer à travers leur système digestif et ont un taux de fer sérique normal à 
élevé. Nous avons donc étudié comment le fer est manipulé dans les réticulocytes de ces 
animaux pour déterminer si la mutation du gène pouvait jouer un rôle dans le 
comportement des organelles qui contiennent la Tf et le fer. L'examen systématique des 
étapes de la voie de la Tf a démontré que le trafic intracellulaire de cette protéine ne 
fonctionnait pas correctement chez les souris hbd. 
Le turnover rapide du fer par les macrophages du RES requière l'enzyme hème 
oxygénase-l (HO-l), qui catalyse l'étape limitante de la dégradation de hème. Il a été 
démontré, par manipulations chimiques ou génétiques, que cette enzyme fortement 
inductible, hormis son rôle principal dans le recyclage du fer par les érythrocytes, confère 
une cytoprotection étonnante aux cellules et aux tissus dans lesquels son taux est élevé. 
En plus du monoxyde de carbone et de la biliverdine, qui ont été démontrés comme étant 
des substances protectrices, les réactions catalysées par HO-I libèrent également du fer 
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ferreux, qui est un fort agent oxydant. D'un autre côté, il est peu probable qu'il existe des 
quantités importantes de hème libre dans la plupart des tissus (c.-à-d., non-érythroïde, 
non-érythrophagocytique), qui puissent fournir des quantités significatives de substrat à 
cette enzyme. De ce fait, il est tentant de spéculer que le mécanisme de cytoprotection de 
l'oxygénase de hème soit détaché de sa fonction dans le catabolisme de hème. Par 
conséquent, nous avons analysé si une augmentation de HO-I dans les cellules peut en 
soit même altérer le métabolisme du fer dans des cellules en culture. Mes expériences 
démontrent, que dans le cas où il n'y a pas de hèmin exogène, le taux de la protéine HO-I 
n'a pas d'effet sur le métabolisme du fer dans les cellules en culture. 
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Chapter 
1 
Introduction 
1.1 Overview of iron metabolism 
1.1.1 Iron in biology 
Early in the archaeon eon (5 billion to 1.5 billion years ago), the Earth's 
atmosphere consisted mostly of nitrogen and carbon dioxide. The predominant form of 
life during that time, cyanobacteria, residing deep in the Earth's oceans, consumed 
carbon dioxide and generated a toxic waste product: oxygen. That oxygen readily reacted 
with soluble ferrous iron (Fe2+) to form insoluble iron compounds which eventually 
became layers ofhematite and magnetite on the, then, ocean floors (what are known to 
geologists as "banded iron formations"). However, after a few billion years, the oceanic 
iron source was exhausted and oxygen was, consequently, free to pollute the Earth's 
atmosphere (1). The pollution of the atmosphere instigated the evolution of organisms 
that could survive not only in the high oxygen environment but also in the context of low 
iron, as iron was, and is, essential for various metabolic pathways. Today, the 
concentration of oxygen in the atmosphere is about 20% and life on Earth is adapted to 
that level, particularly with respect to iron metabolism. 
Iron (Fe) is an absolute requirement for virtually every living organism. 
Numerous, essential, cellular metabolic functions require iron. The metal can be simply 
complexed directly with an enzyme, as in ribonucleotide reductase (required for DNA 
synthesis), part of an iron-sulfur cluster (Ise), as in aconitase (Krebs cycle enzyme), or 
the central component ofheme, as in cytochromes (required for energy metabolism). 
Hemoproteins, in particular, play important roles in biology; in addition to energy 
metabolism, hemoproteins are involved in oxygen binding (hemoblobin [Hb], 
myoglobin) and oxygen metabolism (oxidases, peroxidases, catalase) (2). 
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Ironically, the very properties that afford iron its physiological utility make the 
metal toxic. Through Fenton chemistry, ferrous iron (Fe2+) will catalyze the conversion 
ofhydrogen peroxide to hydroxyl radical, probably the most poisonous oxygen species 
known in biology (3,4). In addition, ferric iron (Fe3+), the oxidized form of the metal, is 
virtually insoluble (10-17 M) under physiological conditions, as it will rapidly form 
insoluble ferric hydroxide in aqueous solutions of pH 7.4 and physiologie oxygen tension 
(5). Therefore, organisms have evolved a myriad of iron binding and transport proteins 
so that they can safe1y an efficiently utilize this biologically dichotomous metal. 
1.1.2 Iron in man 
In hum ans and other vertebrates, iron is required in every cell for essential cellular 
functions, such as electron transfer (cytrochromes) and DNA synthesis (ribonucleotide 
reductase). While aIl cells require iron for normal metabolic function, there are two types 
of tissues which specifically handle iron in a way that affects systemic homeostasis: "iron 
consumers" and "iron suppliers". Though virtually every cell is an iron consumer, 
hemoglobin-producing cells utilize a vast majority (> 80%) of the body's functional iron 
(6, 7) in order, ultimate1y, to maintain sufficient oxygen levels for all of the body's 
tissues. The iron suppliers are mainly macrophages of the liver, spleen, and bone 
marrow, that recycle iron from senescent erythrocytes to the plasma, thus maintaining the 
humoral pool ofbioavailable iron. Human physiology lacks an excretion mechanism for 
fthe metal, however a small amount of iron is lost through desquamation, hair, and finger 
and toe nails (and through menstruation, in premenopausal females). This loss ofiron 
amounts to approximate1y 1 mg daily, a small fraction ofwhat is recycled from senescent 
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Figure 1.1 Mammalian iron cycle. 
Adaptedfrom Pollycove (8). 
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red blood cells, and is replenished by the absorption of dietary iron by gastrointestinal 
enterocytes the other iron supplying cells. Thus, iron completes a systemic cycle with a 
slow trickle of loss and compensatory uptake. 
Figure 1.1 illustrates the mammalian iron cycle and the distribution of the metal. 
Iron is transferred from the gastrointestinal tract to transferrin (Tt), the plasma Fe carrier 
protein (see Section 1.1.3.1), from which it is available to most ofthe cells of the body. 
This transport pool comprises only 3 mg of the total systemic iron, however it tums over 
approximately 10 times daily. Normally, about 1 gram of the body's iron is in excess of 
functional demand and is stored in the liver parenchyma as well as in resident 
macrophages ofthe liver, spleen, and bone marrow. The remainder of the body's iron 
suppl y is part of functional proteins, a vast majority of which is Hb. 
Human disease ensues when iron metabolism is disrupted by 1) hereditary 
disease, 2) iron deficient diet, 3) chronic disease, or 4) chronic blood transfusion. In 
general, limitati~n of functional iron will result in hypochromic, microcytic anemia. This 
condition is most prevalent in developing countries where iron-ri ch dietary sources are 
scarce. The World Health Organization estimates that 1 billion people worldwide suffer 
iron deficiency anemia. Diseases such as rheumatoid arthritis, malignancy, Crohn 
disease, and chronic infections, in which the immune system maintains sustained, 
elevated activity also lead to microcytic, hypochromic anemia, despite normal or elevated 
systemic iron levels. 
Because body iron levels are regulated solely through intestinal absorption, it is 
unlikely that increased dietary intake willlead to iron overload (hemochromatosis) in a 
normal individual. However, there are numerous circumstances in which this condition 
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will occur. The most prevalent ofthese is hereditary hemochromatosis, the most 
common hereditary disease amongst Caucasians. Interestingly, homozygosity for a 
mutation in the gene thought to be responsible for this disease is apparent in about 1 in 
200 Caucasians (9), however as few (9) or fewer (10) than 4% of those actually develop a 
clinical condition. In addition, secondary iron overload occurs in patients who receive 
blood transfusions, especially those suffering from thalassemias. (Thalassemic patients 
also can develop iron overload that is not dependent on transfusion.) In patients with 
severe Fe overload, the deposits ofthe metal are found in the parenchymal tissues ofthe 
liver, pancreas, endocrine glands and other organs. Thus, cirrhosis and diabetes 
frequently accompany hemochromatosis, if the disease remains unmanaged. It is 
important to note that the brain Iikely has organ-specifie mechanisms for regulating iron 
metabolism since the brains ofhemochromatosis patients seldom exhibit any signs of iron 
overload (11). Nonetheless, a number ofneurological syndromes are associated with 
defects in brain iron metabolism (seefollo~ingparagraph). 
The most important type of iron handIing disorder, with respect to my thesis, is 
sideroblastic anemia (SA). Patients afflicted by SA harbour erythroid precursors that 
contain an accumulation of Fe in their mitochondria. The iron-Iaden mitochondria of 
these cells form dense, ring-shaped structures from which the "ringed sideroblasts" get 
their name. The sideroblastic anemias can be inherited (e.g., X-linked SA) or acquired 
(e.g., myelodysplastic syndrome with ringed sideroblasts). Other, diseases that are linked 
to iron metabolism are Parkinson Disease, Alzheimer Disease, Friedreich ataxia (12), 
neuroferritinopathy (13), aceruloplasminemia (14, 15), PANK2 deficiency (16), HO-l 
deficiency (17), DMTl deficiency (18). 
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1.1.3 Iron in cells 
1.1.3.1 Proteins of iron metabolism 
In order to overcome the apparent paradox of requiring the toxic transition metal, 
mammalian physiology has evolved a number of specialized binding, storage, and 
transport proteins to handle iron. Table 1.1 is a list of many of these proteins. 
Table 1.1: Sorne Proteins Involved in Iron Metabolisrn 
ABC-me 
Ceruloplasmin (Cp) 
F erroehelatase 
Mitochondrial transport function 
related to heme synthesis 
Unknown 
t::(~l~ed sideroblasûc ..... 
~;:\; ~îw~ ": . 
\··.·;-.h .. l: -
Regulation of Fe export from cells Neurodegeneration; 
hypochromic micfocytic . 
anemia 
Ferrie reduetase (suggested to 
provide Fe2+ for DMTl in 
duodenum) 
The last enzyme ofheme 
synthesis; Fe2+ insertion into 
protoporphyrin IX 
7 
Unknown 
Erythropoietie 
protoporphyria 
(21) 
(25) 
(27) 
(23,31, 
32) 
Herne oxygenase-l 
(HO-l) 
IRP (1 and 2) 
Melanotransferrin 
Recycling ofhemoglobin Fe 
peptide which inhibits Fe 
absorption and heme Fe recyc1ing 
in macrophages 
Fe "sensors"; bind to IREs 
Unknown 
Mitoferrin (coded for by Fe transport to mitochondria 
frascatl) 
Sideroflexin 1 
Transferrin (Tf) Fe(III)-carrier in plasma 
TfR2 Unknown 
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Severe anemia and 
inflammation 
Juvenile hemochromatosis 
(subtype oftype 2); 
overexpression ofhepcidin 
causes severe Fe deficiency 
anemia 
IRP2: brain Fe overload; 
microcytic anemia 
Unknown 
(17,37) 
(29,43-
45) 
(2,,~;i~),' 
(29,47) 
, (2Q~<48 • 
.. 4~1:;;;;· 
(50) 
·.·.·(Sl.S3y· 
(54) 
U" .... ochtow'é:ané.niia .•. ,' ' ., '(55)" " ".~~J:' ,.". ,',-.,' /'-'0.-"', _, '~, ./~,~",:::;jy ... '-, 
, '? ," (ini~~J:,)t;\~ ,,; ,;~':;~(>" 'T:z~t~~;;,;,~i~~~ :.': 
Severe anemia 
(Fe unavailable for 
erythropoiesis; generalized 
Fe overload 
(29,56) 
1.1.3 .1.1 Transferrin 
Probably the best characterized protein of iron metabolism is transferrin. This 80 
kDa glycoprotein is the major source of iron for virtually all of the tissues in mammalian 
physiology. Tfhas two binding sites for iron, both with very high affinity for the metal 
(Ka= 1 0-23 M). Though it has been shown that the two lobes of transferrin do not have the 
exact same affinity for iron, it is unlikely that their slight difference is relevant to the 
function ofthe protein (62). Nonetheless, all four configurations of Tf (apo, Fe in the N-
terminal lobe, Fe in the C-terminal lobe, holo) have been found in the serum (63). The 
high-affinity binding of iron to transferrin requires both that iron be in the ferric oxidation 
state and the concomitant binding of an anion, normally bicarbonate. Additionally the 
affinity of transferrin for iron is considerably weakened at acidic pH, an important feature 
that has far reaching physiological consequences (see Section 1.2.1). 
Transferrin belongs to a family of iron-binding proteins which inc1udes lactoferrin 
(found in milk, tears, and semen), ovotransferrin (also known as conalbumin; present in 
egg white), and melanotransferrin (a membrane-bound form of Tf) (64). Though all of 
these proteins bind iron, Tfis the only one whose physiological function (to transport 
iron between sites of absorption, storage, and use) has been extensively characterized. 
With the exception of melanotransferrin, whose function has been shown to be re1ated to 
cell proliferation and tumorigenesis (65), the other members ofthis family ofproteins 
have bacteriostatic activity, which is considered to be their major function. Transferrin 
also has bacteriostatic function, though it is unclear whether this has physiological 
significance. These proteins prevent bacterial growth by limiting their iron suppl y and, 
9 
since the majority (~ 70%) of Tf is devoid of iron, it is likely that transferrin also has an 
important role in limiting the availability of iron to infectious microorganisms (66, 67). 
Humans and mice that are Tf deficient develop severely obfuscated body iron 
distribution, with an extreme deficiency in hemoglobin and iron overload in the liver and 
pancreas (68, 69). Importantly, the fact that there still remains a redistribution of iron 
from the sites ofhemoglobin-iron recyc1ing and iron absorption is evidence that 
transferrin is not required for iron release from cells to the plasma. In normal individuals, 
because serum transferrin is such an efficient iron chelator and because it is only about 
30% saturated, there is virtually no other form of iron in the plasma. 
1.1.3.1.2 Transferrin receptor 
In order for cells to remove iron from Tf, the protein must enter an acidic 
compartment within cells (see Section 1.2). Instrumental to that process is the binding of 
Tf to its cognate receptor on the cell surface. The transferrin receptor (TfR) (more 
recently referred to as "transferrin receptor 1", since another protein with considerable 
structural and functional homology has been identified and named "transferrin receptor 
2") is a homodimeric, membrane bound glycoprotein that is present on the surface and 
within intracellular vesic1es of virtually every cell of the body. Each receptor monomer 
is composed of760 amino acids (85 kDa), with a single, 80 amino acid residue 
transmembrane domain and a 61 amino acid cytoplasmic domain (70). The extracellular 
domain of each monomer contains one transferrin binding site. There is a phosporylation 
site at serine 24, although it remains unc1ear whether the phosphorylation status at this 
site is biologically relevant (71). 
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Transferrin receptors are most abundant on erythroid precursors (including 
orthochromatic normoblasts and reticulocytes), hepatocytes, placental trophoblast ceIls, 
endothelial ceIls at the blood-brain barrier, and Sertoli ceIls (blood-testis barrier) (57). 
Elevated TiR levels are also generaIly found on proliferating ceIls (both normal and 
malignant) (72). The only known function ofthis receptor is to mediate iron uptake. In 
most cases, transferrin iron (Fe2 Tf) "uptake" refers to cellular iron uptake, however 
organ uptake may also be mediated by TiR as brain iron levels, which must be derived 
from plasma transferrin, are regulated independently ofthose in the plasma (11, 73). 
Recent evidence suggests that systemic iron levels are tightly regulated by hepcidin (see 
Section 1.1.3.1.6), whose circulating levels are dependent on transferrin saturation (74). 
Additionally the protein whose gene is mutated in most cases ofhereditary 
hemochromatosis (HH), HFE, binds to the transferrin receptor and appears to modify its 
function (75, 76). Thus, it is likely that the transferrin receptor has a role in the control of 
organismal iron uptake. Mice with geneticaIly disrupted TiR die in utero before 
embryonic day 13, and exhibit severe anemia and hypoxia as weIl as defective neural 
development during the earlier days of development (59). Interestingly, mice that are 
heterozygous for ablation of the TiR gene appear similar to wildtype littermates and have 
comparable hemoglobin and hematocrit leveIs; however, closer examination reveals 
hypochromic, micfOcytic red blood cells, as though the animaIs were iron deficient 
(which they are not) (59). Thus, the TfR is crucial for survival of essentially an tissues, 
however reduced expression apparently affects only those cells which are taking up 
extremely large amounts of ifOn for hemoglobin synthesis: erythroid precursors. 
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In most tissues, TfR expression is regulated through a post-transcriptional 
mechanism which couples cellular iron levels inversely with TfR mRNA stablilty 
(described below, Section 1.1.3.2). However, in erythroid precursors, which take up 
considerably more iron than any other tissue to accommodate the massive demand for 
iron for hemoglobin synthesis, the levels of transferrin receptor are primarily under 
transcriptional control (77). 
1.1.3.1.3 Ferritin 
Because of the potential toxicity of "free" iron, excess intracellular Fe must be 
immediatelyand safely sequestered. Ferritin (Ft) is a ubiquitously expressed, 
heteroicoskaitetrameric protein, capable of storing up to 4500 iron atoms in an inorganic, 
paracrystalline form (ferric oxohydroxide phosphate) (28, 78). This protein is comprised 
ofheavy chain (H-Ft; 21 kDa) and light chain (L-Ft; 19 kDa) subunits, whose relative 
proportions in the 24 subunit protein shell vary between tissues. The spleen and liver, the 
major systemic iron storage depots, contain the greatest L:H ratio, while heart and 
skeletal muscle possess ferritins with larger proportions ofH-Ft (28). Physiological 
necessity for iron storage in Ft is evidenced by the embryonic lethality ofH-Ft genetic 
ablation (30). 
The transfer of Fe into ferritin is poorly understood, however it is generally 
believed that Fe2+ enters the shell and is oxidized by the ferroxidase center present on H-
Ft (79). Studies in which homopolymeric ferritins have been generated indicate that both 
heavyand light chain subunits are required for efficient storage of Fe (80). L-Ft, which 
has no ferroxidase activity, is then believed to be necessary for efficient iron storage by 
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containing specific nucleation sites for Fe core fonnation (80). Release of Fe from 
ferritin is likewise poorly characterized. In fact, it is controversial whether Fe can be 
directly released through pores in the Ft protein (81) or if lysosomal degradation is 
required to free Fe from Ft (82). Nevertheless, Fe that has been stored within Ft in the 
liver and spleen is available for hematopoiesis when serum iron levels become depleted 
(6). 
Like TfR levels, those of Ft are controlled primarily via post-transcriptional 
regulation (described below, Section 1.1.3.2) (83); Ft mRNA translation is blocked when 
iron levels are low in the cell and the converse. Additionally, Ft transcription has been 
shown to be affected by non-iron stimuli, though these effects are largely under 
pathophysiological conditions (64). 
1.1.3.1.4 Nramp2/DCTlIDMTI 
Natural resistanc~-assoçiated macrophage protein 2 (Nramp2) was first identified 
by the laboratory of Gros (84) due to its high homology to the Nramp 1 protein, which 
that group demonstrated was mutated in mice susceptible to parasite infection (85). 
Mutations in Nramp2 were subsequently discovered to be responsible for the 
hypochromic, microcytic anemia phenotypes in the mk mouse (86) and Belgrade rat (26). 
Through these models (87,88), as well as in vitro studies (89, 90), it has been established 
that Nramp2 is the transporter responsible for 1) the transport ofintestinalluminal Fe into 
enterocytes and 2) the pumping of intracellular iron out of endosomes (described below, 
Section 1.2). Nramp2 is also known as DMTl (divalent metal transporter 1) and DCTI 
(divalent cation transporter 1) and will be referred to as "DMTl", what has become the 
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dominant title in the literature, for consistency in this thesis. Ubiquitously expressed 
(except in mature erythrocytes), this membrane-associated, 90-100 kDa glycoprotein has 
been shown to transport Fe2+ as weIl as other divalent cations (including Cu2+, Mn2+, 
C02+) in simport with a proton (91). Although it was originally thought that DMTl 
required a proton gradient to transport iron, recent evidence seems to indicate that the 
transporter can efficiently pump Fe2+ without being coupled to H+ movement (92). A few 
recent reports document hum ans with disrupted DMTl (18,93,94). Interestingly, in 
contrast to mk mou se and Belgrade rat, these patients exhibit abnormal iron accumulation 
in their liver in addition to the microcytic, hypochromic anemia observed in the animal 
strains. This inconsistency remains to be explained. 
1.1.3.1.5 HFE 
Hereditary hemochromatosis (HH) is the most common hereditary disease 
amongst Caucasians. Although the penetrance is low, as many as 1 in 200 amongst this 
population are homozygous for the mutated gene (9, 10). Untreated patients suffering 
from HH develop severe iron overload resulting from an apparent unchecked 
upregulation of dietary iron absorption in conjunction with a severe drop in iron retention 
in macrophages (generally accepted to be a major site of iron storage). Although it had 
been known since 1977 that this disease correlated with a genetic abnormality mapping to 
the HLA locus on chromosome 6 (95), it was not until 1996 that the gene responsible was 
identified (36). A cysteine to tyrosine substitution (C282Y) in this gene is present in over 
80% of HH patients (36). Although it was originally referred to as HLA -H, because of its 
close resemblance to HLA class 1 molecules, the protein quickly became known as 
14 
"HFE", somewhat obfuscating the literature which previously used "HFE" to represent 
"hemochromatosis" (96). For clarity, the protein will be referred to as HFE throughout 
this thesis. The HFE protein is expressed in many tissues, however it exhibits 
comparatively elevated expression in hepatic macrophages (Kupffer cells) (97) and crypt 
enterocytes (98). Similar to HLA proteins, HFE is expressed on the surface of cells and 
is associated with ~2-microglobulin (~2m) (99). However, it does not have a sufficiently 
large cleft for presenting antigen. The C282Y mutation interrupts the interaction of HFE 
with ~2m and its subsequent translocation to the surface of cells (99). Consistent with 
this, mice with genetically ablated ~2m exhibit a phenotype virtually indistinguishable 
from HH (100, 101). Transplantation ofthese mice with wild-type bone marrow, will 
redistribute iron from parenchymal cells to macrophages without correcting the defective 
intestinal absorption, confirming that misregulation of macrophage and enterocytic 
function, as the result HFE disruption, forms the basis for the pathogenesis ofhereditary 
hemochromatosis (101). 
Though it has now been over ten years since the cloning of the HFE gene, the 
function of the protein remains enigmatic. Numerous groups have demonstrated that 
HFE binds to TfR and may somehow modulate the receptor's function (102). 
Additionally, mice with ablated HFE do not show the expected response in circulating 
hepcidin levels (103), which are strongly implicated in regulating body iron levels and 
distribution (see Section 1.3.1.1.7 below), indicating that HFE may play a role in the 
hepcidin signalling pathway. 
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1.1.3.1.6 Ferroportin/MTPIIIregl 
In 2000, three independent groups cloned a protein that appears to transport iron 
out of cells (33, 104, 105). Most commonly referred to as ferroportin (FPN), this protein 
is most highly expressed in duodenal enterocytes (33, 104, 105) and macrophages (104), 
but also exhibits elevated expression in the placenta (33). Later studies demonstrated a 
depletion ofintracellular iron leve1s upon overexpression of FPN, confirming its role as 
an iron exporter (106, 107). Sequence analysis predicts ferroportin to be an integral 
membrane protein having ten transmembrane domains (104). Interestingly, the 
subcellular localization of this transporter appears to be primarily intemalized within the 
cell (104), rather than at the cell surface. This is consistent with the apparent intracellular 
localization ofhephaestin, a membrane-bound, multi-copper oxidase of intestinal cells 
that is be1ieved to drive the provision of oxidized iron for binding to Tf in the plasma (42, 
108). Thus, it is possible that iron export entails exocytosis of the metal, preceded by its 
transport by FPN into an exocytic compartment. It is important to note that the 
requirement for a multi-copper oxidase for efficient transport by ferroportin is the only 
evidence that this protein transports the ferrous form of iron (105). 
The mRNA encoding ferroportin contains an iron response element in its 5'-
untranslated region (see Section 1.1.3.2) (33, 104). The response offerroportin 
expression to cellular iron levels still remains unclear; one would expect macrophages 
that are recycling iron from senescent erythrocytes to provide the metal to plasma Tf, or 
duodenal enterocytes that are mediating nutritional iron absorption, to receive their cues 
not from their own cellular iron levels, but from a signal reflecting organismal iron 
demands. Indeed, recent evidence has suggested that FPN levels or activity may be 
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coupled to plasma iron concentration by the small, antimicrobial peptide, hepcidin (see 
Sections 1.1.3.1.8 and 5.1) (106, 109, 110). 
Interestingly, an autosomal dominant form ofhereditary hemochromatosis 
resulting from mutation of the FPN gene, termed "ferroportin disease" has been described 
in a number of families (111). This is seemingly in conflict with the apparent 
requirement of FPN for efficient transfer of iron to the plasma and the observation that 
zebrafish lacking the FPN gene have severe iron deficiency anemia (33). This paradox 
may possibly be explained by an as yet undiscovered route of iron through the gut that 
responds to decreased plasma iron resulting from the phagocytic iron retention. 
1.1.3.1.7 Herne Oxygenase 
Herne oxygenases (112) catabolyze the rate limiting step in heme degradation 
which entails the conversion ofheme to equimolar amounts ofbiliverdin, carbon 
monoxide, and Fe2+. The inducible isoform ofthe enzyme has been designated herne 
oxygenase 1 (HO-l) and is responsible for the turnover of Fe from the heme of effete 
RBCs, about 2 million ofwhich are being destroyed per second in a normal adult. Two 
other HO isoforms have been identified in mammals, HO-2 (113), which is constitutively 
expressed and mostly confined to the testes and nervous system, and HO-3, whose 
expression and role remain mostly unknown but is unlikely to be relevant (114, 115). 
Aiso known as HSP32, HO-l is a 32 kDa protein, anchored in the endoplasmie 
reticulum (ER) by hydrophobie amino acid residues in the protein's carboxyl terminus 
(116). This enzyme is highly inducible and will increase in response to a vast variety of 
stimuli, inc1uding heme and other metalloporphyrins (117, 118), transition metals (117, 
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119), cytokines (120, 121), hypoxia (122), hyperoxia (123), ultraviolet irradiation (124), 
heat shock (125), and reactive oxygen species (ROS) (126). Accordingly, the promoter 
region ofthe HO-1 gene is a target ofnumerous transcription factors (127). Among these 
is Bach-1 (128, 129), a transcriptional repressor that becomes deactivated upon binding to 
heme. Thus, Bach-l is thought to be the major mediator of metalloporphyrin induction of 
herne oxygenase-l. In contrast, reactive oxygen species and those substances that lead to 
cellular glutathione depletion, including sodium arsenite, appear to control HO-l 
transcription through an AP-l binding site in the gene's promoter region (130). 
Although the Fe recycling role ofheme oxygenase has been known since the 
work of Tenhunen, Marver and Schmid in 1968 (131), the ubiquitous expression and 
ability of this enzyme to be efficiently upregulated by non-heme stimuli suggests an 
additional role for HO-1 in mammalian physiology. Indeed, more recent research has 
attributed a potent cytoprotective role to heme oxygenase (132-136). Induction or 
overexpression ofHO-l or HO-2 in a widespread number of tissue in jury models have 
demonstrated that heme oxygenase can increase cell or tissue survival. In addition, mice 
or cells having an ablated HO-l gene exhibit elevated sensitivity to oxidative stress (137). 
The only known human deficiency in HO-1 (17) manifested far more seriously than the 
murine condition. This patient displayed severe growth retardation, numerous abnormal 
blood indices, endothelial detachment of the renal glomeruli, and iron deposition in the 
liver and kidney (17). It is believed that the extensive endothelial injury apparent in this 
patient is the result of increased susceptibility of the endothelium to oxidative stress. 
Importantly, the precise mechanism by which HO-1 conf ers cytoprotection remains 
elusive. 
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Since the only known reaction catalyzed by HO is the degradation ofherne, 
researchers have focussed their studies on exploring the protective potentials of two-
thirds ofthe reaction's products: biliverdin and CO. Biliverdin, itselfreportedly 
possessing antioxidant activity, is readily converted by biliverdin reductase to bilirubin, 
which has been shown to have considerable antioxidant properties (138, 139); chernically 
sirnilar to nitrogen rnonoxide (NO) (140), CO rnay act as a gaseous second rnessenger, 
binding to the herne group on guanylate cyclase or other hernoproteins to initiate a 
protective intracellular signalling cascade (141-143). Though a potent pro-oxidant itself 
(see Section 1.1.1 above), iron stirnulates the synthesis of Ft which, it has been suggested, 
ultimately reduces the levels of intracellular, catalytic iron, thereby preventing further 
ROS production (144). However, the most enigmatic aspect ofthese hypotheses is the 
availability ofsubstrate for HO. Approximately 97% of the body's heme is bound to 
hemoglobin or myoglobin, with a substantial amount of the remaining 3% in hepatic 
cytochromes (6) (a Iso see Table 4.1). AIso, it has been estimated that free, intracellular 
herne levels are below 30 nM (145). Thus, it appears that the amount of "free" heme 
available for HO in most cells would be extremely limited. 
1.1.3.1.8 Other proteins of iron metabolism 
A number of proteins, other than those detailed herein, contribute in varying 
degress to cellular and organismal iron metabolism. Sorne of these proteins are described 
in Table 1.1. Of particular relevance to iron uptake are two very recently identified 
proteins: Steap3 and mitoferrin. The former is a membrane-spanning protein with 
elevated levels in erythroid tissues implicated in reducing iron that has been released in 
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the transferrin endosome for subsequent transport by DMTl (which requires Fe2+ as a 
substrate) (see Section 1.2 below) (55). Mitoferrin is a mammalian homolog ofthe 
mitochondrial proteins Mrs3/4, which are partially responsible for mitochondrial iron 
acquisition in yeast. Mutation of the zebrafish gene, known as frascati, was shown to 
cause severe hypochromic anemia that could be rescued by introduction of the gene 
encoding murine mitoferrin (50). The characteristics of other iron-related proteins are 
beyond the scope ofthis thesis and will not be described at length. However, one protein 
has recently emerged which seems to have a very important regulatory role, necessitating 
its mention in this work. Hepcidin is a small (20 or 25 amino acid residues), 
antimicrobial peptide. Found in the plasma and urine, hepcidin apparently controls 
plasma iron levels by acting on macrophages which are tuming over iron from senescent 
RBCs (39, 106, 109, 146, 147) as weIl as duodenal enterocytes that are involved in iron 
absorption (148). The mechanisms ofhepcidin regulation and the precise functioning of 
the pepti,de still require more rigorous research, though it is clear that the discovery of 
this peptide will have profound implications for iron metabolism research. 
1.1.3.2 Regulation ofproteins ofiron metabolism by the IRE/IRP system 
As alluded to earlier, regulation of cellular iron levels and distribution is largely 
under the control of a post transcriptional regulatory mechanism. The untranslated 
regions (UTRs) of various mRNAs encoding proteins involved in iron metabolism 
contain one or more of a highly conserved, stem-Ioop structure known as iron responsive 
elements (IREs) on the UTR found either on the 5' end or the 3' end of a given message. 
This structure consists of a loop sequence 5' -CAGUGN-3' situated "on" a double-
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stranded he1ix of 5 complementary nucleotides, with a lower "stem" portion of variable 
length situated, "below" an asymmetrical bulge (149). Two cytoplasmic proteins, known 
as iron regulatory proteins (IRPI and IRP2), will, under certain circumstances, bind to 
these stem loop structures (44, 150) (Figure 1.2). IRP binding to an IRE in the 5'-UTR of 
a message, as in that for Ft, wi11lead to blockage oftranslation of the mRNA. In 
contrast, when IREs are present in the 3' -UTR of an mRNA, as is the case for TfR, IRP 
binding willlead to stabilization of the message, resulting in increased protein 
expression. Table 1.2 contains a list of the various proteins whose mRNAs contain 
IREs. 
Table 1.2 Proteins with IREs present in their messenger RNAs 
Ferritin H-chain 
Ferritin L-chain 
ALA-S2 
Mitochondrial aconitase 
Mitochondrial succinate 
dehydrogenase (D. melanogaster 
only) 
Transferrin receptor 
DMTl (splicing determines 
presence of IRE) 
Ferroportin 
5'-UTR 
5'-UTR 
5'-UTR 
5'-UTR 
3'-UTR 
3'-UTR 
5'-UTR 
Iron storage 
Iron storage 
Rate-limiting enzyme of 
protoporphyrin IX synthesis 
Krebs cycle 
Krebs cycle 
Gatekeeper of Fe uptake in most 
tissues 
Endosomal and intestinal Fe 
transport (IRE splice variant is 
predominant in the gut) 
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Figure 1.2 Post-transcription al regulation of lRE-containing rnRNAs. 
When IRPs bind to a 5'-UTR IRE (e.g., ferritin), translation is blocked, while binding to 
an IRE in the 3' -UTR (e.g., transferrin receptor) leads to mRNA stabilization. 
Adaptedfram Kim and Panka (153). 
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The regulation of IRP binding activity (illustrated in Figure 1.3) has been a 
subject ofnumerous studies since the discovery of the IRE/IRP system in the mid 1980's. 
Although IRPI and IRP2 bind to the same RNA stem-Ioop structure and have 
considerable sequence resemblance (57% identity and 75% similarity), the mechanisms 
goveming the binding activities ofthese two proteins are quite distinct. IRPI operates 
like a molecular switch: in Fe replete conditions, a cubane iron-sul fur cluster (4Fe-4S) is 
present on the protein, simultaneously conferring aconitase activity and inhibiting IRE 
binding (154, 155); when cellular iron levels are low, the ISC dissociates from IRP1, both 
removing the protein's aconitase functionality and allowing a conformational change that 
gives rise to a high affinity for IREs (156). In contrast, the protein levels ofIRP2, which 
contains no ISC (157), determine this protein's IRE binding activity. It has been 
demonstrated that a unique, cysteine-rich stretch of 73-amino acids within the N-terminal 
portion of IRP2 includes a motif that grants iron-dependent susceptibility of the protein to 
degradation through the ubiquitin-proteasome pathway (158-160). It is important to note 
that the IRPs' binding activities are modulated not only by iron, but also by sorne non-
iron stimuli including oxidative stress (161), nitrogen monoxide (also referred to as 
"nitric oxide"; NO) (162-165), oxygen tension (126, 166), and phosporylation (167). 
The relative contributions to cellular iron metabo1ism of the two IRP isoforms 
remain to be uncovered. Mouse knockout studies have demonstrated that IRP2 may be 
the dominant iron-controlling isoform, as IRPI-1- mi ce exhibit no explicit pathological 
phenotype (168), while IRP2-1- mice have erroneous iron metabolism regulation in the 
intestine, central nervous system (CNS) (resulting in a neurodegenerative disorder in 
adult life (169)), and erythroid tissues (resulting in hypochromic/microcytic erythrocytes) 
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Figure 1.3 Regulation of IRPs activities. 
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IRP2 activity is decreased by proteasomal degradation. Both of these conditions are 
sensitive to iron. 
Adaptedfrom Kim and Ponka (153). 
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(45, 170). In vitro experiments employing tissue culture models ofiron metabolism also 
have implicated IRP2 as the dominant iron regulatory protein (164, 171). 
1.1.3.3 Herne biosynthesis 
Eight enzymes participate in the biosynthetic pathway which generates heme, this 
Fe-containing tetrapyrrole (or porphyrin) which participates in numerous, essential 
cellular functions (in addition to its role in hemoglobin for systemic oxygen transport). 
Half of these eight enzymes reside in the mitochondria, inc1uding the first and last 
enzymes of the pathway, 5-aminolevulinic acid synthase (ALA-S) and ferrochelatase 
(FC), respectively (Figure 1.4). These two enzymes are of particular importance in iron 
metabolism. 
ALA-S catalyzes the first and rate-limiting step in the synthesis of protoporphyrin 
IX, one of the substrates for ferrochelatase (FC): the condensation reaction between 
succinyl CoA and glycine, requiring pyridoxal 5' -phosphate (PLP) as a cofactor, to form 
5-aminolevulinic acid (ALA) (172-174). Two isoforms ofthis enzyme exist. ALA-Sl, 
or the "housekeeping" ALA-S, is encoded on chromosome 3p21 and ubiquitously 
expressed, while ALA-S2 (a.k.a., e-ALA-S) is located on the X chromosome and specific 
to hemoglobin-producing tissues (175, 176). As one would expect, the regulation of 
heme synthesis via this enzyme is widely divergent between tissues that express one or 
the other isoform. Seminal investigation by Granick demonstrated that ALA-S 1 is 
inhibited by hemin (177). Early studies suggested that this mechanism was via feedback 
inhibition by the ultimate reaction product in the pathway, heme (178, 179). It has sin ce 
been demonstrated that these studies employed non-physiological conditions (180); the 
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Figure 1.4 The herne biosynthetic pathway. 
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repression of ALA-Sl by herne is now believed to be prirnarily by both decreasing the 
half-life ofits rnRNA (181) and blocking the entry of the protein into rnitochondria (182). 
Herne, as weIl as aIl of the intermediates along the pathway, are potentially toxic to cells, 
so this negative feedback loop serves to tightly coordinate herne synthesis with cellular 
dernands. Additionally, transcriptional regulation of the ALA-Sl gene is controlled via 
NRF-l (183), a transcription factor involved in the maintenance of cellular respiration 
(184). 
In erythroid cells, vast arnounts ofhernoglobin are being produced for efficient, 
systernic oxygen transport. This requires stringent coupling of iron uptake, herne 
synthesis, and globin sysnthesis, due to the potential toxicities ofherne and iron. Herne 
levels conduct these concerted pathways by both rnodulating globin translation through 
the herne-regulated inhibitor (HRI) (185, 186) (Figure 1.5), and affecting transferrin-iron 
uptake into the cell (23, 187). However, iron is the cornponent whose availability is 
lirniting hernoglobin synthesis (188-190). Accordingly, the erythroid-specific isoform of 
ALA synthase is subject to post-transcriptional regulation by the IRE/IRP system; the 
rnRNA for ALA-S2 contains an IRE in its 5' UTR. Hence, when iron availability is low, 
translation of ALA-S2 will be blocked, reducing porphyrin (and, therefore herne) 
synthesis which, in tum, both permits increased Fe2Tfuptake and reduces globin 
synthesis. 
Ferrochelatase is the final enzyme in the herne biosynthetic pathway. This 
rnitochondrial enzyme catalyzes the insertion of iron into PPIX to form herne. 
Interestingly, rnammalian FC contains an Fe-S c1uster which is essential for its enzymatic 
activity (191, 192). When there is not sufficient iron available for FC, as in iron 
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Figure 1.5 Regulation of globin synthesis by herne. 
When herne levels decrease, HRI becornes activated and phosphorylates a subunit of the 
translation initiation factor, eIF-2. Since the nuc1eotide ex change factor, eIF-2B, is 
unable to efficiently recycle phosphorylated eIF-2-GDP to eIF-2-GTP, translation of 
globin (and other proteins which require eIF-2) will be halted. 
Adaptedfram Panka (193). 
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deficiency anemia, the enzyme will utilize zinc (Zn) in its place to form Zn-
protoporphyrin IX (ZnPP), whose levels in RBCs can be used to assess diseases of iron 
metabolism, in particular, iron deficiency or iron-deficient erythropoiesis (194). 
Importantly, for it to be a substrate for FC, iron has to be in the +2 oxidation state. 
Disruption of the delicate balance of iron uptake, globin production, and heme 
synthesis in erythroid tissues inevitably results in pathological situations. Porphyrias 
develop when a deficiciency in an enzyme in the heme synthesis pathway arises, leading 
to an accumulation oftoxic porphyrin intermediate(s) when the lack ofheme allows a 
dramatic increase of ALA-S levels (195, 196). The only enzyme ofthe eight involved in 
heme synthesis, whose deficiency or mutation do es not result in a porphyria, is ALA-S 1. 
When the erythroid isoform (ALA-S2) ofthis enzyme is mutated, as in X-linkded 
sideroblastic anemia (XLSA), iron accumulates in the mitochondria of erythroblasts, in 
which cells a ring ofiron-Iaden mitochondria is observed (197) (see a/sa section 1.1.2). 
The accumulation of Fe in the mitochondria <?f erythroid cells can be reproduced in vitro 
by treating cells with either isonicotinic acid hydrazide (INH; inhibitor of ALA-S) or 
succinylacetone (SA; inhibitor of ALA dehydratase [second enzyme in the heme 
biosynthetic pathway]) (198-202). 
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1.2 Cellular iron uptake 
1.2.1 Transferrin endocytosis 
As mentioned above, plasma Tf is a very efficient iron chelator and is normally 
only 30% saturated, thus existing as the only source of iron in the plasma. With the 
notable exceptions of enterocytes and macrophages-and, of course, mature red blood 
ceIls-aIl ceIls of the body therefore must acquire iron via transferrin. Figure 1.6 depicts 
the pathway for iron uptake. FezTfbinds to the transferrin receptor on the ceIl surface, 
triggering receptor-mediated endocytosis (see Richardson and Ponka (29) for review). 
Subsequent to intemalization, diferric Tf enters an endosomal compartment where the 
activity ofthe v-ATPase proton pump lowers the pH ofthe compartment to around pH 
5.5. Under these acidic conditions, the affinity of Tf for iron is considerably diminished, 
allowing release of the metal into the endosome. With the proton gradient providing a 
driving force, DMT1 transports the iron out ofthe organelle (88-90). Since this 
transporter is specifie for only divalent metals (91), and Tfbinds Fe3+, the irou must be 
reduced before its egress from the endosome. Ohgami et al. recently identified a 
candidate protein, Steap3, for this putative ferrireductase (55). 
Receptor-mediated endocytosis is a complex process that involves coordination of 
a variety of pro teins whose functions include targeting, signaIling, docking, and 
movement (for review, see Mukherjee et al. (203) and Maxfie1d and McGraw (204». In 
most cells a range ofligands are intema1ized through receptor-mediated endocytosis, 
though the handIing of these materials ultimately varies depending on the nature of the 
1igand's usage by the cell. The general pathway begins with the recruitment of clathrin 
through signalling by the cytop1asmic domains of the surface receptors to form a pit. 
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Figure 1.6 Transferrin endocytosis. 
[1] Diferric transferrin binds to TfR on the cell surface. [2] A clathrin coated pit fonns 
which matures into an endosome. [3] An ATPase H+ pump acidifies the endosome. 
When the pH falls below 5.5, Fe3+ dissociates from Tf [4] After reduction, possibly by 
Steap3, Fe2+ is transported out ofthe endosome by Nramp2 [DMTl]. The released iron 
is now available for utilization by the cell. [5] Apo-Tf remains bound to the receptor at 
low pH; the acidified vesicle is retumed to the cell surface, thus recycling the Tf and the 
TfR. Apo-Tf is release from the receptor when it reaches plasma pH levels. 
Adaptedfrom Ponka and Lok (57). 
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After this pit is intemalized to produce a clathrin-coated vesicle, the organelle loses its 
clathrin and combines with other new or already formed endosomes to form what is 
referred to as a sorting endosome. Following its presence in the sorting endosome, Tfhas 
been observed in the endosomal recycling compartment (ERC), a collection of tubular 
structures associated with microtubules (204). It is unclear, at this point, where iron is 
released from Tf, however it is generally believed that the TfR -Tf complexes are recycled 
from the ERC to the plasma membrane for reuse. 
The targeting and fusion of endosomal compartments within the cell and with the 
plasma membrane involves docking proteins, ofwhich SNARES (soluble N-
ethylmaleimide-sensitive fusion protein attachment protein receptors) are likely 
candidates. These proteins are present on vesicles (termed v-SNAREs) and have binding 
partners on their "target" compartments (t-SNAREs). In transferrin cycling, cellubrevin 
(also referred to as VAMP3) and been shown to be involved in the fusion oftransferrin-
containing vesicles with plasma membrane (205). In addition, the vesicular fission 
molecule, dynamin, has been implicated in the formation ofTf-containing, recycling 
vesicles (206). The family of small GTPase regulatory proteins, known as Rab proteins, 
also appear to play an important role in transferrin endocytosis. Rab5 has been shown to 
mediate formation of the sorting endosome by regulating fusion between early vesicles 
and this later structure in conjuction with EEAI (early endosome antigen-I) (207). Rab4 
and Rab II also appear to be involved in the Tf cycle (204). 
Although the only known function of Tf is to deliver iron to cells (and, in 
vertebrates, most organismal iron is used for Rb synthesis), a vast majority ofthe 
trafficking studies conducted thus far have been in non-erythroid cells. Rence, it is 
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important that future studies investigate the roles of SNARE, Rab, and other proteins in 
the movement and regulation of iron transport into hemoglobin-synthesizing cells. 
1.2.2 The labile iron pool 
Iron that is taken up by a cell via transferrin endocytosis will ultimately reach one 
of four compartments: 1) heme, 2) Fe-S cluster, 3) Non-herne, non-ISe functional 
proteins, or 4) ferritin. However, the pathway ofiron trafficking from its exit from the 
endosome to its delivery as a substrate to processing proteins (i.e., ferrochelatase, ISe 
biogenesis enzymes, ferritin) rernains almost totally enigmatic. It is widely accepted that, 
upon its flow out of the endosome, iron enters a cytosolic, intermediate pool comprised of 
a low-molecular weight iron intermediate, which functions to supply iron to sites of 
utilization (208, 209). However, despite decades of investigation, the nature of this 
putative intermediate remains elusive, causing researchers to liken it to the Loch Ness 
monster (210). 
The idea of a labile iron pool (LIP) was first demonstrated in 1962 by Pollycove 
and Maqsood, who observed a bone marrow-associated, non-heme iron fraction that was 
utilized by cells for heme synthesis (211). They and others (212-215), mainly using cell 
fractionation and protein purification techniques, appeared to identify different Fe 
intermediates in Hb-producing tissues. Further characterization of these iron moieties 
was limited, and more recent investigations have demonstrated that when radioiron is 
supplied to erythroid tissues, virtually no intracellular radioactivity is present in a non-Tf, 
non-herne form (216, 217). However, addition of chelators to non-erythroid cells will 
mobilize intracellular iron (218-220); moreover, under artificial conditions, iron can even 
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be mobilized from erythroid precursors (217, 221-223). In the CUITent literature, this 
chelatable iron has been considered to be interchangeable with the intracellular labile iron 
and, thus, the LIP has been inappropriately defined not as an absolute cellular 
concentration, but adynamie amount dependent on the action of an investigator' s chosen 
chelator. A recent study by our laboratory has demonstrated that there is ,,:irtually no 
chelatable iron in reticulocytes fed 59Fe2Tfifthe cells are held at 4°C during the time of 
chelation, suggesting that the access of chelators to iron requires that the metal is being 
actively metabolized (217). It is important to note that the pathway of iron from the cell 
surface to its intracellular targets in Hb-synthesizing cells may be distinct from that in 
non-erythroid cells (23). 
1.2.3 Utilization of intemalized iron 
A vast majority of functional iron is processed in the mitochondria. Although 
there has been controversy regarding the location of the assembly of ISCs onto 
cytoplasmic proteins (224, 225), it now seems more than likely that all cellular Fe-S 
clusters are assembled in the mitochondria (19). Moreover, as mentioned above, FC, the 
enzyme which carries out the final step in herne synthesis to insert Fe into PPIX, resides 
in the mitochondria. The mechanism(s) ofiron delivery to mitochondria is one of the 
largest gaps in our understanding of iron metabolism. Mutational studies in zebrafish 
have possibly uncovered a mitochondrial iron transporter, dubbed mitoferrin (50). Short 
ofthis very recent discovery, virtually nothing is known about mitochondrial iron uptake 
and handling. It is important to reiterate (see Section 1.1.3.3) that disruption ofheme 
biosynthesis in erythroid tissues (198-202) as well as abrogation of iron-sulfur cluster 
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biogenesis (see Lill and Kispal (226) for review) willlead to profound iron accumulation 
in mitochondria. 
1.2.4 Non-transferrin bound iron uptake 
Physiologically, non-phagocytic, non-enteric cells are only exposed to the 
transferrin form of iron. In addition transferrin is the only source of iron for erythroid 
cells (69, 227-229). However, in cases ofiron overload, such as untreated hereditary 
hemochromatosis or transfusional iron overload, transferrin can be fully saturated, giving 
rise to iron that is loosely bound to serum components (230, 231). Primarily through the 
work of Morgan's group, it has been documented that erythroid ceIls (223) and 
hepatocytes (232) (cells which are adversely affected by iron overload) are able to take 
up non-transferrin bound iron (NTBI). After the discovery ofDMT1, and its localization 
to the plasma membrane (233), it is now likely that any ceIl which expresses the divalent 
tran~porter, which includes all cells that take up iron via Tf, is capable of accumulating 
NTBI. Additionally, recent evidence appears to indicate that the proton gradient 
previously thought to be required as a driving force for Fe translocation via DMTl, may 
not be essential for the activity ofthis transporter (92). Importantly, the known pathways 
ofiron passage through DMTl (i.e., intestinal absorption and endosomal export) entail 
movement of the metal along a concentration gradient. 
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1.3 Iron metabolism in "iron suppliers" 
1.3.1 Macrophage biology 
Derived from hematopoietic stem cells, macrophages' roi es in physiology are 
manifold, accordingly exhibiting wide divergence between distinct tissues. Although 
splenic and hepatic (and, to a lesser degree, bone marrow) macrophages are responsible 
for the rapid and constant turnover of Fe from senescent erythrocytes, the primary role of 
the macrophage, in general, is in host defence. These phagocytic cells, also referred to as 
the reticuloendothelial system (RES) in the context of Fe metabolism, will engulfforeign 
pathogens for both clearance and antigen presentation. In order to perform their 
microbicidal functions, macrophages become primed and then activated upon exposure to 
proinflammatory cytokines (e.g., interferon-y [IFN-yD and pathogenic antigens (e.g., 
lipopolysaccharide [LPSD, respectively. This macrophage "activation" is the 
culmination of various signalling pathways, ultimately equipping the cell with its full 
compliment of microbicidal m~chinery, including the capacity to generate large 
quantities of nitrogen monoxide. 
Macrophages also act as scavengers to clean up stray cellular debris and proteins 
that are present pathologically. This function may be relevant to iron metabolism in 
cases ofhemorrhage or other conditions which entail an increase in extracorpuscular 
hemoglobin and heme. Plasma proteins hemopexin and haptoglobin are specialized 
heme- and hemoglobin-binding proteins, respectively, both ofwhich are believed to be 
removed from the circulation primarily by hepatocytes and macrophages (234). 
Candidate receptors for heme-hemopexin (235) and hemoglobin-haptoglobin (236) 
complexes have been identified, however it remains questionable whether hemopexin or 
36 
haptoglobin play significant roles in physiological Fe metabolism, as their genetic 
ablation in mice does not elicit phenotypes of disturbed organismal iron distribution (237, 
238). 
1.3.2 Macrophage iron metabolism 
Despite their major contribution to systemic iron metabolism, the cellular 
handling of iron by macrophages remains largely elusive. Senescent erythrocytes, 
identified as senescent by macrophages through a number of possible signaIs (reviewed 
in Bratosin et al. (239) and Knutson and Wessling-Resnick (240» are engulfed by 
macrophages and enter a digestive compartment in these cells. The heme prosthetic 
group from Hb, through an unknown pathway, arrives at HO-l, which is an insoluble 
membrane-associated protein in the ER. It is possible that heme is readily available to 
this compartment as Desjardin's group has demonstrated that the ER can supply 
membrane directly to the phagosome (241). After the liberation, of Fe, the cellular 
localization or chemical nature of the iron remains unknown. Ultimately, the bulk of 
erythrophagocytosed Fe will either become incorporated into ferritin or re1eased to 
plasma transferrin via ferroportin, the only known mammalian iron exporter that releases 
Fe from cells for loading onto Tf (see Section 1.1.3.1.6) (33, 104, 105). The serum, 
copper-containing oxidase, ceruloplasmin (Cp), is required for the efficient release of Fe 
from macrophages; it is therefore believed that FPN specifically transports Fe2+. Figure 
1.7 depicts a current model of macrophage iron metabolism. 
RES macrophages express measurable levels ofTfR and will endocytose Fe2Tf 
(242) and take up Fe from Tf (243), however the majority ofiron entering RES 
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Figure 1.7 Macrophage iron metabolism. 
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Effete erythrocytes are phagocytosed and their heme catabolized by H 0-1. The iron is 
then either released from the cell by ferroportin ("FPNI "), whose activity is coupled to 
oxidation ofthe iron by ceruloplasmin ("CP"), to forrn Fe3+ which is then available to 
bind apo-Tf, or stored in Ft. It is unlikely that holo-Ft is released from cells, however 
sorne early reports describe this phenomenon (244, 245). Macrophages also express TfR 
and will take up transferrin iron. In addition, Nramp 1 (natural resistance-associated 
macrophage protein 1) is a putative iron transporter involved in innate immune protection 
from pathogens (246). The scavenger receptor CD 163 has been documented to take up 
hemoglobin-haptoglobin (Hb-Hp) complexes (247). 
Adaptedfrom Knutson and Wessling-Resnick (240) 
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macrophages is probably in the form of erythrocytic hemoglobin. Importantly, these cells 
are considered to be major iron storage sites (240). Hence, macrophages are in a unique 
position to regulate systemic iron availability. In fact, Fillet, Cook, and Finch 
demonstrated in vivo in 1974 that erythrophagocytosed Fe is released from macrophages 
in two phases: a rapid phase (ty, = 34 min) which normally accounts for two-thirds of the 
Fe utilized daily and a slower phase (ty, = 7 days), therefore supplying most of the 
remaining third. Depending on serum iron turnover, and not serum iron levels, the 
amount of erythrophagocytosed Fe entering these two pathways is redistributed to meet 
fluctuating demands for iron (248). It is unclear whether the erythropoiesis-stimulating 
humoral factor, erythropoietin (EPO), has a direct effect on macrophage Fe handIing, 
however mounting evidence points to hepcidin as a factor which, responding to Tf 
saturation (110), can control the release of Fe from RES macrophages, possibly by 
decreasing levels offerroportin (FPN) (106). Importantly, these cells express significant 
amounts of the HFE protein (97), which plays a crucial, though unknown, role in 
regulating circulating iron levels, possibly within the hepcidin signalling pathway (103). 
As discussed above, evidence that HFE has a key role in iron metabolism cornes from the 
fact that a vast majority ofhereditary hemochromatosis patients have mutations in the 
gene encoding HFE. 
1.3.3 Enterocyte biology 
The polarized epithelial cells that line the small intestine control the absorption of 
many cell membrane impermeable nutrients. Connected by tight junctions, these cells 
express a barrage of nutrient transport proteins who se levels or activity vary depending 
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on systemic demands. The cens most involved in absorption reside in the villi, fingerlike 
projections into the intestinal lumen. Specific regulation of absorption through villus 
cells can occur at the brush-border membrane (BBM) of the cens, which faces the lumen, 
and at the basolateral membrane (BLM), resting on the "blood" side of the mucosa. The 
regions deep in the troughs between villi are known as the crypts of Lieberkühn and 
contain cells that maintain the composition of the mucus. Importantly, these cells 
differentiate and travel into the villi to replace cells which are regularly sloughing off the 
intestinallining. Thus, the epitheliallining is totally replaced every three days. Because 
ofthis dynamic equilibrium, it is possible that crypt cens become "programmed" to 
contain specific transport systems, as they differentiate, based on cues from the blood 
(249,250), though limited research has focussed on this aspect of intestinal absorption. 
The alternative hypothesis to this is that terminally differentiated enterocytes regulate 
protein expression to modulate the absorption of specific nutrients. 
1.3.4 Enterocyte iron metabolism 
Similar to macrophages, enterocytes have a regulatory role as regards body iron. 
Since mamrnals cannot ex crete iron, organismal balance is rnaintained solely by 
regulation of intestinal absorption. Because of the rapid turnover of enterocytes, it may 
be possible that a limited arnount of iron clearance may be achieved by the sloughing off 
of cells that have taken up sorne iron from the circulation. In support of this, it has been 
demonstrated that enterocytes frorn animaIs fed an iron rich diet take up more 59Pe2+_ 
transferrin e9PeTf) than normal controls (251). However, research on this possible 
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pathway has not been confinned and it remains unclear whether it would be feasible for 
the body to rid itself of significant amounts of iron through this mechanism. 
Nutritional iron is believed to be absorbed through two distinct mechanisms; 
though these pathways probably converge at sorne point before transfer of the metal to 
the plasma, it is wide1y accepted that dietary heme and non-heme iron enter intestinal 
cells differently. The mechanism ofheme uptake across the intestinal epithe1ium and its 
movement to herne oxygenase (associated with the ER) has yet to be described. 
Recently, Shayeghi et al. (252) identified a candidate, BBM heme transporter, however 
this finding has yet to be confinned. Non-heme Fe3+ is soluble only at low pH and 
therefore its absorption occurs primarily in the proximal duodenum where there is both a 
re1atively acidic environment as well as a proton gradient to provide energy for transport 
by DMTl. Before it can be transported, Fe3+ must be reduced and a candidate 
ferrireductase enzyme, duodenal cytochrome b (Dcytb), has recently been implicated in 
this task (27). However, animaIs in which the gene encoding Dcytb has been ablated do 
not appear to have a deficiency in iron absorption, indicating either that Dcytb has a 
different function or that there is redundancy in the proteins capable of reducing Fe3+ in 
the intestinal lumen. Once Fe2+ enters the intestinal cell through DMTl, it is completely 
unknown what fonn it may take in the cell, or even in what compartment the Fe may be. 
Somehow, ferrous iron arrives at the basolateral aspect ofthe enterocytes where it is 
released to the portal circulation by FPN. Again, because transferrin binds only ferric 
iron with high affinity, an oxidation step is required before the absorbed Fe is finally 
donated to the blood for use in the body. This is achieved by the ceruloplasmin homolog, 
hephaestin (Heph), a membrane bound version of the multi-copper oxidase (42). 
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From the point of view of iron metabolism, crypt enterocytes share many 
similarities to RES macrophages. At their basoloateral aspects, they express HFE (98) 
and TfR and bind Fe2Tf(251, 253). Also akin to macrophages, absorptive enterocytes 
are likely to take up comparatively more non-transferrin iron (from the intestinal lumen) 
than via the TfR pathway (at the BLM). Thus, the mechanisms ofregulation ofbody iron 
levels by enterocytes parallels, in part, that of macrophages (for review, see Roy and 
Enns (254», but may also involve proteins of iron metabolism that are specifie to 
enterocytes, namely Heph and Dcytb. In addition, a response known as "mucosal block" 
has been described whereby large amounts ofluminal iron rapidly downregulate 
intestinal iron absorption (255-257). VirtuallyaIl of the studies describing this 
phenomenon are experimentaIly tlawed in that they supply an initial, unlabeled dose of 
Fe into the digestive system, succeeded by a smaIl bolus of radiolabeled Fe as a tracer. 
The observed decrease in iron transfer to the plasma can be explained by a dilution of the 
radioiron by the cold Fe already intemalized by enterocytes, rather than a decrease in 
specifie iron transport mechanisms. Henee, it remains to be understood whether villus 
enterocytes alter the expression levels or activities of iron transporters or whether these 
ceIls are programmed before their differentiation along the crypt-villus axis. 
Nonetheless, the recent observation that hepcidin may bind to FPN to downregulate its 
activity probably provides a mechanism of rapid control over intestinal absorption at the 
level of the villus eeIl. 
1.3.5 Iron and intlammation 
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Also known as anemia of inflammation (AI), anemia of chronic disease (ACD) 
(for reviews, see Thomas and Thomas (258) and Weiss and Goodnough (259)) is one of 
the most common forms of anemia in industrialized nations. This condition is most 
frequently observed in patients with rheumatoid arthritis, infection, and cancer (260). In 
a nutshelI, ACD is the result of the folIowing, pathogenic triad: retention ofiron in RES 
macrophages, reduction in iron release from stores, downregulation of intestinal 
absorption of the metal. It is presumed that this rapid decrease in the availability of 
functional iron serves to deprive pathogenic organisms of Fe, precipitating a reduction in 
their ability to proliferate and survive. Interestingly, this iron-starved condition do es not 
pose apparent advantages to those patients suffering from ACD of a non-infectious 
etiology (e.g., rheumatism, malignancy). 
AlI of the pathogenic events associated with ACD are directed by cues generated 
by the immune system. In macrophages, it has been shown that nitric oxide generation 
during inflam.mation causes the degradation of IRP2 via the ubiquitin-proteasome system, 
which leads to a subsequent increase in ferritin synthesis associated with an escalated 
iron storage in this protein (261, 262). However, it appears that hepcidin, whose hepatic 
release has been shown to be elicited by both LPS and IL-6 (generated by activated 
macrophages), may be the major acute factor regulating the iron limitation in ACD 
patients (263). Recent results suggest that hepcidin may bind to and inhibit (by eliciting 
lysosomal degradation) FPN, thus reducing the release of iron to transferrin by both 
macrophages and intestinal celIs (106, 264). 
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1.4 Rationale of Studies 
1.4.1 "Kiss and run" hypothesis for iron uptake in erythroid precursors 
In view of the potential toxicity of iron, especially in the oxygen-rich environment 
ofthe differentiating erythroid precursor, the efficiency by which these cells utilize iron 
is astounding. Considering this, it is surprising how poorly the iron transport system in 
hemoglobin-synthesizing cells is understood. Furthermore, it is essential that this system 
be characterized in order to develop therapies to treat patients with anemia from low 
hemoglobin of differing etiologies (e.g., iron deficiency anemia, sideroblastic anemia, 
functional ifOn deficiency anemia). My study examines the possibility that, in erythroid 
precursors, transferrin-derived iron is transferred directly from endosomal protein to 
mitochondrial protein, bypassing the cytosol. Due to the wide divergence in membrane 
compositions, we do not hypothesize that these organelles fuse, rather that the iron is 
handed over from one to the next. Thus, there will be an intermediate condition at which 
time iron will be bound by neither com~artment. We propose that this requisite, though 
fleeting, intermediate step provides the iron which is available for chelation in studies 
where a UP is reported. It is important to note that the work described in this study 
specifically addresses only those cells which are differentiating into erythrocytes. 
1.4.2 Characterization of the functional defect in hbd/ hbd mice 
The second part of my studies investigates the possibility that mutation of a 
protein involved in the hypothesized interaction between endosomes and mitochondria 
for iron transfer is responsible for the phenotype of a mouse mutant, the "haemoglobin-
deficit" (hbd) mouse. In 1969, Scheufler described a spontaneous mouse mutation which 
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manifested itself as an iron deficiency anemia (265). Since that time, it has been 
demonstrated that these hypochromic, microcytic mice have normal serum iron levels and 
decreased iron uptake exclusively in erythroid tissues (266-269). Additionally, the gene 
responsible, Secl511, has recently been identified (51, 52). Its yeast homolog is involved 
in the exocytosis pathway, however no functional studies of this protein have been 
carried out in mammalian cells. Considering my previous results which demonstrate that 
endosomal motility is required for efficient delivery of Fe to mitochondria, it is very 
likely that Secl511 is a necessary component oftransferrin-endosome cycle. My study 
systematically examines the steps in the transferrin cycle in order to determine what 
aspect oftransferrin-iron acquisition is affected in hbd reticulocytes. 
1.4.3 Effect ofheme oxygenase-l induction on iron metabolism 
The major role ofHO-l in mammalian physiology is to recycle iron from the 
heme of senescent erythrocytes. In about the last decade, numer~us reports have 
attributed a new role to this enzyme: the protection of tissues. Because the only known 
function ofHO-l is in the catabolism ofheme, it has been continuously asserted that the 
cytoprotective capacities ofthis enzyme are attributable to its ability to catabolyze heme. 
However, it appears that there would be very little heme available for this function (see 
Table 4.1). Furthermore, the liberation of catalytic Fe2+ could potentially counteract the 
alleged detoxifying properties of carbon monoxide and biliverdinlbilirubin. Therefore, in 
order to determine whether there may be another mechanism of HO-l function (e.g., 
another substrate), we investigated the consequences ofincreasing heme oxygenase-l 
levels on iron cellular iron and heme metaboIism. The absence of any changes in cellular 
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iron horneostasis when HO-l levels are increased to protect cells (without supplying 
herne) would indicate that the rnechanisrn of the protective action ofHO-l involves a 
distinct, non-herne pathway. 
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Chapter 
2 
Direct interorganellar transfer of iron from endosome to 
mitochondrion 
2.1 Preface 
The study presented in this chapter builds upon the recent research in our 
laboratory that shows a crucial role for endosomes in directing iron to mitochondria, the 
sites ofheme synthesis (reference 22 of the following manuscript). In that previous 
work, we demonstrated that the myosin motor is likely to be required for the proper 
targeting of iron to the mitochondria in reticulocytes. In addition, we showed that when 
these cells are not actively acquiring iron, there is virtually no labile iron intermediate 
present for a chelator to bind. Although these results are congruent with our hypothesis 
that iron is directly delivered to mitochondria through an interorgannellar association of 
endosomes and mitochondria, further research was required to demonstrate this 
interaction and provide proof of its functional necessity. Therefore, we investigated the 
trafficking of iron in reticulocytes taking not only a novel biochemical approach, but also 
imaging strategies to examine whether transferrin-containing endosomes associate with 
mitochondria in erythroid precursors. 
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2.2 Abstract 
Iron is a transition metal whose physicochemical properties make it the focus of 
vital biological processes in virtually allliving organisms. Among numerous roles, iron 
is essential for oxygen transport, cellular respiration, and DNA synthesis. Paradoxically, 
the same characteristics that biochemistry exploits make iron a potentially lethal 
substance. In the presence of oxygen, ferrous iron (Fe2+) will catalyse the production of 
toxic hydroxyl radicals from hydrogen peroxide. Additionally, Fe3+ is virtually insoluble 
at physiological pH. To protect tissues from deleterious effects of Fe, mammalian 
physiology has evolved specialized mechanisms for extra-, inter-, and intra-cellular iron 
handling. Here we show that developing erythroid cells, which are taking up vast 
amounts of Fe, deliver the metal directly from transferrin-containing endosomes to 
mitochondria (the site ofheme biosynthesis), bypassing the oxygen-rich cytosol. Besides 
describing a new means of intracellular transport, our finding is important for developing 
therapies for patients with iron loading disorders. 
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2.3 Introduction 
Although its requirement for life in almost aIl known organisms has been 
recognized for decades, sorne of the most fundamental, cell biological processes of iron 
(Fe) still elude modem science. Mammalian physiology demands a constant source of 
bioavailible Fe, which is a functional component ofhemoproteins, iron-sulfur cluster 
containing proteins, and other iron proteins. However, inappropriate distribution of this 
metal contributes to or causes disease. In addition to having a direct causative role in the 
pathology ofiron overload disorders, such as hemochromatosis or thalassemias (via 
transfusional overload), Fe has been implicated in the development ofneurological 
disorders, including Parkinson's disease (1), Alzheimer's disease (2), and various ataxias 
(3). 
In its reduced form (Fe2+), iron catalyzes the production oftoxic hydroxyl radicals 
through Fenton chemistry, while the ferric version (Fe3+) is virtually insoluble at 
physiological pH (4-6). Nevertheless, the adult human body contains approximately 4 g 
of Fe, over 80% ofwhich is in hemoglobin (Hb) (7). Under normal conditions, around 2 
million red blood cells (RBCs) are produced per second. Hence, erythropoiesis requires 
approximately 25 mg ofiron, daily, all ofwhich is delivered via transferrin (Tf). The 
plasma contains about 3 f.lM diferric Tf, the Fe ofwhich is concentrated in maturing 
erythroid tissue to the equivalent of 20 mM iron, in the form of Rb. This exceptionally 
rapid utilization of the potentially toxic metal requires stringent regulation mechanisms 
that permit efficient production ofhemoglobin, while protecting developing red blood 
cells and other tissues from iron's harmful properties (8). 
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Virtually every tissue acquires its iron by receptor mediated endocytosis of Tf (for 
review, see Richardson and Ponka (9) and Hentze et al. (10): Diferric Tfbinds to its 
cognate receptor on the cell surface; this binding is succeeded by intemalization of the 
receptor-ligand complex. The release of Fe from Tfis achieved within the endosome by 
a lowering of the vesicular pH through the activity of the v-ATPase proton pump. After 
its liberation from Tf in the acidified endosome, Fe must be reduced (possibly by the 
recently identified Steap3 (11» before it is transported across the vesicular membrane by 
the divalent metal transporter (DMT1 / Nramp2 / DCT1; henceforth referred to as 
"DMT1") (12-14). 
The immediate fate of iron, after having been exported from the endosome, is 
largely unknown. Through sorne mechanism, the metal must move from the vesicular 
exporter, past both mitochondrial membranes, to the matrix, where the enzyme that 
inserts Fe2+ into the protoporphyrin IX (PPIX) ring, ferrochelatase (FC), resides (10, 15, 
16). Shaw et al. (17) recently identified a mitochondrial inner membrane protein that is a 
likely candidate for a mitochondrial iron importer. Interestingly, inhibitors ofheme 
biosynthesis (isonicotinic acid hydrazide, succinylacetone) (18-22) or mutation of a heme 
biosynthetic enzyme, 5-aminolevulinic acid synthase (i.e., patients with X-linked 
sideroblastic anemia) (23) cause Fe to accumulate in the mitochondria ofHb producing 
cells (yielding ringed sideroblasts in the latter example), demonstrating that iron 
delivered to these cells is specifically targeted to the mitochondria. 
The accepted model for iron transfer from the transferrin-containing endosome 
proposes that endocytosed iron is exported to the cytosol and complexes with sorne low 
molecular weight carrier, to form what is generally known as the labile iron pool (LIP) 
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(24, 25). However, this much sought after iron complex has never been identified. 
Furthermore, ferrous iron, the substrate ofDMTl, would be considerably toxic in the 
oxygen-rich cytosol of the developing erythroid cell (26). Importantly, previous results 
from our laboratory, which demonstrate that there is virtually no chelatable iron in 
reticulocytes that are not metabolically active, are in conflict with the generally accepted 
characterization of the UP (27). The present study exploits reticulocytes, which are 
acquiring vast amounts of iron for Hb synthesis, to examine the delivery of iron from the 
endocytic vesic1e to the mitochondria. 
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2.4 Materials and Methods 
2.4.1 Materials 
Unless stated otherwise, aIl chemicals were acquired from Sigma-Aldrich 
(Oakville, ON). AIl 37°C incubations with reticulocytes were performed using MEM 
supplemented with 1 % bovine serum albumin (BSA), 25 mM HEPES, and 10 mM 
sodium bicarbonate, pH 7.4 (henceforth referred to as "incubation medium"), unless 
otherwise noted. 59Fe2Tfwas made by generating 59Fe-citrate from 59Fe-chloride 
(dissolved in 0.5 M HCI; Perkin Elmer, Woodbridge, ON) and labeling apo-Tf, as 
previously described (28). 59Fe-salicylaldehyde isonicotinoyl hydrazone e9Fe-SIH2) was 
generated by adding 59Fe-citrate (20: 1 molar ratio of citrate to 59FeCh) to two molar 
equivalents of SIH (synthesized as previously described (29)), dissolved in 0.05 N 
NaOH, to yield 25 /-lM Fe-SIH2 in incubation medium and left for 60 min at room 
temperature. An additional amount ofNaOH volumetric standard was added to the 
medium before adding the iron and SIH solution, so that the resulting incubation medium 
would be pH 7.4. Radioactivity measurements were performed using a Cobra II gamma 
counter (Packard Instruments, Meriden, CT). Confluent dishes of Huh7 ceIls 
(hepatocyte-like cellline) were generously provided by Dr. Kostas Pantopoulos. B-
[(2,2' -bipyridin-4-yl)aminocarbonyl]benzyl ester (RDA) was a generous gift of Dr. 
Reiner Sustmann (University of Duisburg-Essen, Germany). 
2.4.2 Transient Lysis - Resealing of Reticulocytes 
Reticulocytes were extracted via cardiac puncture, with a heparinized syringe, 
from CD-l, female mi ce that had been treated for three consecutive days with 50 mg/kg 
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phenylhydrazine (administered intraperitoneally) and allowed to recuperate for 2 or 3 
days (i.e., mice were bled on day 6 or 7 from first injection). This method aIlowed us to 
harvest blood that contained 30-50% reticulocytes (verified by new methylene blue 
staining) and these sampI es will be henceforth referred to as "reticulocytes". The cells 
were washed 3 times in phosphate buffered saline (PBS) and resuspended in a minimal 
volume ofPBS, containing 1 mM of a membrane impermeant form of desferrioxamine 
(HES-DFO; Biomedical Frontiers, Inc., Minneapolis, MN) or fluorescein isothiocyanate-
dextran conjugate (10,000 kDa; FITC-dextran) where indicated. Lysis and resealing 
were performed according to the method of Scott et al. (30). Briefly, lysis was 
accompli shed by loading the cells into dialysis tubing (approx. 300 ~1/15 cm of Il mm 
diameter, 3500 molecular weight cut-offtubing) and dialyzing against 5 mM potassium 
phosphate buffer (pH 7.4) for 20 min at 4°C. The tubes were immediately placed in an 
isotonic solution (5 mM potassium phosphate buffer with 0.9% NaCI and 0.1 % glucose), 
which was prewarmed to 37°C, and incubated for 30 min at that temperature. After this 
resealing step, the cells were washed in ice cold PBS 3 to 5 times, until the supernatant 
became c1ear. 
2.4.3 Iron Uptake and Incorporation into Herne 
For aIl incubation steps, a 10-20% hematocrit of the reticulocyte suspension was 
used. For resealed cens: Washed, resealed cells were incubated for 60 min at 37°C in 
incubation medium to remove HES-DFO that may have accumulated within vesic1es. 
These cens were subsequently treated with 1 ~M 59Fez-Tf or 59Fe-SIHz for 2.5 hrs at 
37°C. After washing the cens 3 times with ice cold PBS, the heme and non-heme 59Fe 
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were separated by an acid lysis / trichloroacetic acid precipitation method that was 
previously described (18, 27). 
For experiments with non-resealed reticulocytes, washed cens were incubated for 
60 min at 4°C in the presence of 1 IlM 59Fe2-Tf. A cohort of 59Fe labeled endosomes 
were generated in these cens by adding bafilomycin AI (bafilomycin; 60 nM; inhibitor of 
v-ATPase responsible for endosomal acidification (27,31)) for the last 30 min ofthis 
incubation and then warming the cens to 37°C for 30 min In a previous report, we 
loaded endosomal vesicles by incubating reticulocytes for a short period at 37°C (27). 
The method in the CUITent study improves upon this technique by anowing a greater 
amount of radioiron loading into the cens, with a lower baseline 59Fe-herne synthesis 
after loading. Unbound 59F e2-Tf and bafilomycin was removed by washing the cens in 
PBS and surface-bound radioactivity was removed by a 120 min treatment at 4°C with 10 
IlM 56Fe2_ Tf (i.e., non-radioactive diferric transferrin). The cens were next treated with 
the indicated concentrations ofN-( 6-aminohexyl)-5-chloro-I-naphthalene-sulfonamide 
(W-7) for 30 min at 4°C. Incorporation of 59Fe into herne was monitored by incubating 
the samples at 37°C for the indicated time intervals, washing in PBS, and determining the 
heme and non-heme radioactivity as mentioned above. Treatment with W-7 for 
microscopy experiments was done similarly (i.e., 30 min at 4°C and left in the media 
during fluorescent Tfuptake). 
Por non-TfPe uptake experiments: 59Pe-ascorbate (59PeAsc) was generated by 
combining 59FeCh with a sodium ascorbate solution to yield a molar ratio of 1 :44 (iron to 
ascorbate). 59FeAsc or 59Fe-Tf2 was then immediately added to the reticulocytes to reach 
the indicated final concentrations and the cens were incubated for 30 min The cens were 
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then washed in ice cold PBS and treated for 30 min with 1 mg/mL pronase to remove any 
radioactivity bound to proteins at the cell surface. 
2.4.4 Iron Chelation 
Reticulocytes' vesicles were loaded with 59Fe as described above (using 
bafilomycin) and treated with W-7 also as described above. Where indicated, 1 mM 
dipyridyl (DP) was added immediately before warming the samples to 37°C, (both DP 
and W -7 remaining present during this incubation period). After this final incubation 
step, the cells were pelleted, lysed by adding 300 ~l ddH20, and the chelator-bound 
fraction extracted by adding 1 mL ice-cold ethanol and leaving ovemight at 4°C. This 
treatment yields an insoluble protein fraction, which contains the protein-bound 59Fe, and 
an ethanol soluble fraction, which is the chelator-bound radioiron (27,32). The pellet 
from this step was washed once in ice-cold ethanol. Radioactivity in the incubation 
medium, ethanol pellet, and ethanol supematants was measured by gamma counting. 
Counts from the ethanol soluble fraction represented the cell-associated, chelator bound 
Fe and were added to the radioactivity of the media to calculate "released" iron, which 
was subsequently compared to the total radioactivity of the sample (cells plus media) to 
determine the degree of iron release as a percentage of the amount that the cell originally 
took up. 
2.4.5 Con/ocal Microscopy 
Washed reticulocytes were resuspended in incubation medium (approx. 10 million 
cells / mL) and treated with 500 nM MitoTracker Red CMXRos (Molecular Probes) for 
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20 min at 37°C. Excess fluorescent probe was removed by washing the samples 3 times 
with ice cold PBS. The samples were resuspended in Iscove's modified Dulbecco's 
media (IMDM) and transferred to a glass coverslip bottom culture dish (MatTek) and 
placed on the stage of a Zeiss LSM 510 meta (Carl Zeiss GmbH) confocal inverted 
microscope that had been outfitted with a heated stage (37°C) and a Plan-Apochromat 
100x objective with a numerical aperture of 1.4. Before image acquisition, 500 ~L of 
prewarmed (37°C) Alexa Green 488 transferrin (AG-Tf; 500 nM; Invitrogen, Carlsbad, 
CA) were added. Using the Zeiss LSM 510 software, a multi-channel proto col was used 
to scan the sample once for each fluorochrome every 50 milliseconds, 400 times, yielding 
20 second videomicrographs with a framerate of 20 / sec. Vesicular movement was 
tracked using MetaMorph™ (Univers al Imaging, Molecular Devices, Sunnyvale, CA). 
Loading of mitochondria with rhodamine B-[ (2,2' -bipyridin-4-
yl)aminocarbonyl]benzyl ester (RDA) was performed as previously described for RP A 
(33). Briefly, the reticulocytes were incubated at 37°C for 25 min in 300 nM RDA, 
washed three times with PBS, and reincubated for at 37°C for 20 min. Cells were washed 
two more times in PBS, resuspended in IMDM, and loaded onto coverslip bottom culture 
dishes. Live imaging was performed as described above. 
For plasma membrane labelling, reticulocytes or Huh7 cells, in IMDM 
supplemented with 10% fetal calf serum, were incubated with 2.5 ~g/mL or 0.5 ~g/mL, 
respectively, N -(3-triethylammoniumpropyl)-4-( 4-( dibutylamino )styryl) pyridinium 
dibromide (FM 1-43; Invitrogen) at room temperature for 10 minutes in coverslip bottom 
dishes and subjected to confocal microscopy, using a 63x objective (NA 1.4). Where 
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indicated, 500 nM Alexa Green 488-Tf was added at the same time as the plasma 
membrane label. 
2.4.6 Electron Microscopy 
Reticulocytes were incubated with 1 ~M HRP-Tf(Jackson ImmunoResearch 
Laboratories, West Grove, PA) at 37°C for 10 min, washed three times in ice-cold PBS, 
and fixed with 2.5% glutaraldehyde. HRP was developed by suspending the fixed cells 
in a 1 mg/mL solution of diaminobenzidine (DAB) in PBS, adding H202 (BioShop) to 
0.01 %, and incubating at room temperature for 30 min Developing was halted by 
washing the cells with PBS, following which the cells were resuspended in 2.5% 
glutaraldehyde and processed as previously described for EM: osmication, dehydration, 
infiltration with epon, and ultra-thin sectioning (34). 
2.4.7 Data Analysis 
Representative video segments in which relatively immobile mitochondria 
appeared to be contacted by one or more AG-Tf were selected for analysis. Using 
MetaMorph software, a region of interest was drawn around either a mitochondrion, or 
segment of a mitochondrial network, labeled with RDA. The area encompassed not only 
the organelle, but also included sorne space (approximately 20 nm) outside the organelle 
on the aspect facing an approaching endosome. Measurements of the average intensity 
within the region of interest for each signal with respect to time were made for the image 
time series using MetaMorph. Data was pasted into SigmaPlot (SPSS, Inc.), smoothed 
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(using a running average algorithm with sampling proportion set to 0.100), normalized to 
the maximum intensity for each signal, and plotted. 
AIl of the results presented are representative of at least four replicate 
experiments. Error bars represent standard deviations. 
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2.5 Results 
2.5.1 Ironfrom transferrin-containing endosomes can bypass the cytosol. 
We have exploited a technique, previously used only with RBCs, to load 
reticulocytes' cytosol with the membrane impermeant chelator, HES-DFO (see Materials 
and Methods). To verify that the reticulocyte membrane is as amenable to transient 
hypotonie lysis and resealing as that of the erythrocyte, we loaded blood cens, harvested 
from phenylhydrazine treated mi ce, with fluorescein isothiocyanate-dextran. To 
differentiate between RBCs and reticulocytes, the cens were subsequently labeled with 
MitoTracker Red CMXRos. As depicted in Figure 2.IA, reticulocytes took up a 
significant amount of the fluorescent conjugate, while retaining sound morphology. 
After confirming that reticulocytes can be resealed with high molecular weight 
compounds, we loaded these cells with HES-DFO. Reticulocytes with cytoplasmic HES-
DFO incorporated an equivalent amount ofradioiron, from 59Fe2-Tfinto herne compared 
to controls (Figure 2.1B), indicating that Tf borne 59Fe cannot be intercepted by the 
chelator. To confirm that the chelator was taken up by the cens and that it is available to 
bind cytosolic Fe, the resealed cens were incubated in the presence of 59Fe-SIH2, a 
membrane permeable complex that is able to provide Fe for heme biosynthesis (35, 36). 
Indeed, the incorporation of 59Fe into heme, in cells containing HES-DFO, was 
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Figure 2.1 Cytoplasmic HES-DFO does not block 59Fe2_ Tf incorporation into herne. 
Reticulocytes were exposed to transient lysis and resealing, as described in Experimental 
Procedures. (A) Cells were resealed in the presence of FlTC-dextran (green), treated 
with MitoTracker CMXRos (red), and evaluated by confocal microscopy. (B) Cells were 
resealed in the absence or presence of 1 mM HES-DFO and then treated with either 1 /lM 
Fe-SIH2 or 1 /lM 59Fe2-Tffor 2.5 hr at 37°C. Herne and non-heme fractions were 
separated, measured by gamma counting, and the percentage of cell-associated 59Fe in 
heme was plotted. Error bars represent standard deviations. 
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compromised when we used this fonn ofiron. Together, these data indicate that Fe 
derived from Tf-containing vesicles can reach ferrochelatase, on the mitochondrial inner 
membrane, without entering a chelatable, cytoplasmic pool. 
2.5.2 Inhibition of vesicular motility blocks Fe incorporation into heme. 
Using bafilomycin, an inhibitor ofthe v-ATPase proton pump, we created a 
cohort of 59Fe2-Tfladen vesicles within reticulocytes. Since iron will not be released 
from Tfuntil the vesicular pH is lower than 5.5, when bafilomycin-treated reticulocytes 
were incubated in the presence of 59F er Tf, the iron entered the endosomal compartment 
but remained therein. After washing out the inhibitor, the radioiron was available for 
heme biosynthesis (Figure 2.2, 60'). Confoeal mieroseopy of retieuloeytes treated with 
this inhibitor and subsequently incubated with Alexa Green 488-Tf(AG-Tf) yielded 
videomicrogaphs qualitatively identieal to those acquired in the absence ofbafilomycin 
(see "Transferrin-containing vesicles co.ntact mitochondria" section below). 
When added to reticulocytes before addition of AG-Tf, the specifie calmodulin 
inhibitor, W -7, completely blocked endocytosis (Supplemental Video 2.1). If we added 
the W-7 after a brief37°C incubation in the presence of AG-Tf, the already fonned 
vesicles are eompletely immobilized (Supplemental Video 2.2). To investigate the effect 
of inhibition of vesicular movement on the delivery of iron to FC, we first treated 
reticulocytes with bafilomycin, wanned the cells in the presence of 59Fe2-Tf, and washed 
the inhibitor and unbound 59Fe2-Tffrom the cells. The samples remained on ice for two 
hours in 10 ~M 56Fe2-Tfto displace any surface-bound radioiron transferrin. As 
mentioned above, when these reticulocytes were wanned to 37°C, the 59Fe from the 
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Figure 2.2 Endosomal motility is required for 59Fe availability. 
The endosomal compartment of reticulocytes was loaded with 59Fe2_ Tfby treating the 
cells sequentially with bafilomycin (60 nM; 30 min at 37°C) and 59Fe2-Tf(1llM; 30 min 
at 37°C). Where indicated, increasing concentrations ofW-7 were inc1uded in the 
reincubation step (60 min at 37°C). The incorporation of 59Fe into heme is shown as the 
percentage of total cell-associated 59F e. 0', before reincubation; 60', 60 min reincubation 
(in the absence of W -7). Error bars represent standard deviations. 
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loaded vesic1es was incorporated into heme; however, when W-7 was added to the cells 
prior to (and during) warming, utilization of the vesicular 59Fe was blocked (Figure 2.2). 
To make sure that W -7 do es not directly inhibit heme biosynthesis, we loaded 
reticulocyte mitochondria with 59Fe, using succinyl acetone as previously described (20, 
22), washed out the inhibitor, treated the cells with W-7, and incubated the cells at 37°C 
for an hour. The cells treated with W-7 did not show any significant decrease in Fe 
incorporation into herne compared to untreated controls (data not shown). Together, 
these data indicate that free, vesicular iron is not simply exported from the vesic1es; 
movernent of the organelles is required for proper targeting of the metal to mitochondria. 
2.5.3 Chelation of59Fe requires vesicular movement 
We have previously shown that chelation of iron from reticulocytes, the vesicles 
ofwhich have been loaded with 59Fez-Tf, requires that the cells be metabolically active; 
that adding chelators at the time of lysis at 4°C do es not result in a significant increase of 
chelator bound iron versus time oftreatment with the iron source (27). To test whether 
the delivery of Fe to chelators depends on vesicular movement, we loaded reticulocytes' 
endosomes with 59Fe2-Tf, as described above, treated the samples with W-7, and added 
chelator (100 !lM DP) immediately before incubation at 37°C. Figure 2.3 illustrates that 
without chelator, reticulocytes with vesic1es loaded with 59Fe2-Tfwill release sorne iron 
(about 12% ofthat taken up at the maximum) over the time interval. This unexpected 
finding was probably a result ofbafilomycin treatment, since it was not observed when 
vesicles were loaded by a 1 min incubation period (37°C; no bafilomycin present), as we 
have previously reported (27). As expected, the presence ofDP dramatically increased 
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Figure 2.3 Endosome motility enhances chelatability of endosomal 59Fe. 
Cells were prelabeled with 59Fe2-Tf, using bafilomycin, as in Figure 2.2. After labeling, 
unbound 59Fe was removed and dipyridyl (DP) and/or W-7 (or neither) were added to the 
cells, as indicated. The tubes were incubated at 37°C and sampi es were drawn at the 
indicated time points for evaluation ofthe chelated/released fraction. The amount of 59Fe 
bound to chelator intracellularly (i.e., ethanol soluble) was added to that measured in the 
culture medium and displayed as a percentage of the total amount of radioactivity in the 
sample. ~" control; _, W-7; +, dipyridyl; ., both W-7 and dipyridyl. Error bars represent 
standard deviations. 
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the amount ofreleased iron (to about 28% at 60 min). Interestingly, W-7 considerably 
decreased the release of vesicul ar 59Fe by DP, implicating a necessity for endosomal 
motility in generating chelatable iron from 59Fe2_ Tf (Figure 2.3). Identical experiments, 
using 100 !lM SIH in place ofDP generated virtually identical results (data not shown). 
2.5.4 Cytoplasmic, 'free" Fi+ is ineJJiciently utilized. 
According to our model, efficient transfer of iron to mitochondria occurs through 
a transient interaction between the endosome, which contains a high concentration of 
iron, and the mitochondrion. Therefore, we predicted that the utilization of"free" ferrous 
iron in the cytosol for heme synthesis would be comparatively inefficient. Because 
DMTl resides at the cell surface before endocytosis (37) and is also functional at pH 7.4 
(38), it was possible for us to artificially create a "UP" in reticulocytes by incubating 
them in the presence of 59Fe(II)-ascorbate. Somewhat surprisingly, at pH 7.4, uptake of 
the ferrous ascorbate was more efficient than that of Fe2Tf (Figure 2.4), at the higher 
concentrations, indicating that DMT1 is not limiting in Fe2Tfiron uptake. Importantly, 
even though the cellular uptake was up to over two-fold greater (on a per cell basis), the 
proportional utilization ofthe intracellular 59Fe was much lower when 59Fe(II)-ascorbate 
was used as compared to 59Fe2 Tf; at 2 !lM for both forms, uptake was approximately 
equivalent, yet the percentage of Fe in herne for the Tf sample was about 92%, while that 
of the ferrous ascorbate sample was only about 24%. This finding stresses the key role of 
the Tf-Tf receptor pathway in the highly efficient use of Fe for heme synthesis. 
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Figure 2.4 Utilization of 59Fe from Tf is more efficient than from 59Fe-ascorbate. 
(A) Concentration dependence: cens were incubated for 30 min with the indicated 
concentrations of either 59FerTf or 59Fe(II)-ascorbate and the heme and non-heme 
fractions measured and displayed as pmol Fe per million cens. (B) Time dependence: 
cens were incubated in 2 /lM 59Fe2_ Tf or 59Fe(II)-ascorbate for the indicated times and 
analysed as in Panel A. Error bars represent standard deviations. 
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2.5.5 Transferrin-containing vesicles contact mitochondria. 
To visualize the movement of endosomal vesic1es with respect to mitochondria, 
we used confocal microscopy to examine cells that were doubly fluorescence labeled. 
Reticulocytes with MitoTracker Red CMXRos-stained mitochondria were incubated on a 
heated (37°C), confocal microscope stage in 500 nM AG-Tf. Images were acquired at 20 
frames per second, allowing real time evaluation of the X-y position oftransferrin-
containing endosomes; aU videomicrographs were recorded within 20 minutes of the 
addition of the cells to the Tf solution. Binding and intemalization of the AG-Tf 
occurred immediately. At least three populations of organelles containing fluorescent 
green label can be distinguished (Figure 2.5A; Supplemental Video 2.3): (1) small, 
extremely motile, (2) large, moderately motile, (3) large, mostly immobile vesic1es. The 
former two species can be seen to transiently abut one or more mitochondria within the 
20 second video capture. The interaction between the larger organelles and the 
mitochondria are usually less transient that that of the smaller vesic1es. Additionally, we 
quantitatively tracked the most motile vesic1es in the X-Y plane and found that their 
average velocity was 2.77 ± 0.43 flm/S. These videos c1early dernonstrate that the Fe2-Tf 
containing vesic1es penetrate considerably the reticulocyte cytosol and repeatedly get 
very close to or touch mitochondria. 
Using TE M, we verified that the Tf-containing endosomes actually touch 
mitochondria in these cells. The vesic1es, identified by staining with HRP-Tf, appeared 
either as part of an endosomal network (Figure, 2.5B-C) or solitary vesic1es (Figure 
2.5D). Web-like endosomes similar to the ones we have documented here, were 
88 
previously observed by Stoorvogel et al. (39) and it is likely that the individual structures 
we observe 
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Figure 2.5 Transferrin-containing vesicles move to mitochondria. 
(A) Confocal miCfograph time series of a representative reticulocyte with labeled 
mitochondria (red) and holo-transferrin (green). Panels proceed from left to right with a 
50 ms interval. Arrows in the leftmost panel of each row highlight sorne of the vesic1es 
that appear to interact with mitochondria over the course of the videomicrograph. Cell 
diameter is approximately 8 /lm. The corresponding videomicrograph is shown in 
Supplemental Video 2.3. (B-D) TEM images ofreticulocytes labelled with HRP-Tf. M, 
mitochondrion; arrows indicate HRP-Tf. Scale bar is 200 nm. 
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are simply cross-sections through the network. Importantly, both these structures 
appeared to be intimately associated with mitochondria (Figure 2.5B-D) in numerous 
sections. The developing ofHRP-labeled compartments with DAB treatment allowed us 
to visualize the compartments that contained the Tf. In cells where we did not apply the 
conjugated protein, we were unable to visualize the endosomal networks. We speculate 
that osmication alone was insufficient to label these organelles in reticulocytes, since the 
high concentration ofhemoglobin blunted the contrast profile of our samples. 
In an attempt to investigate whether Tf-containing endosomes specifically, or 
more frequently, "contacted" mitochondria compared to vesicles with sorne other cargo, 
in our live imaging system, we labeled reticulocytes with both AG-Tf and FM 1-43, a 
fluorescent probe that targets membrane phospholipids. Interestingly, when these dual-
labeled reticulocytes were incubated in the presence of full media (containing 10% fetal 
calf serum), all ofthe endocytotic vesicles contained transferrin (Figure 2.6A). These 
data suggest that Tf is virtually the only endocytosed ligand in reticuloc):1es, precluding 
any examination of the trafficking of a FM 1-43-only compartment. As a positive 
control, we labeled Huh7 (hepatocyte cellline) similarly and show endocytosis of 
membrane phospholipid into vesicles devoid of fluorescent transferrin (Figure 2.6B). 
AIso, we were unable to observe any uptake of fluorescent insulin in reticulocytes, while 
it was readily endocytosed in Huh7 cells (data not shown). 
2.5.6 Endosome-mitochondrion interaction increases chelatable mitochondrial iron. 
To investigate whether the observed interorganellar contacts were functional 
interactions, we loaded reticulocytes' mitochondria with a fluorescent metallosensor and 
91 
A 
B 
Figure 2.6 In reticulocytes, ail plasma membrane-derived, intracellular structures 
contain transferrin. 
cens were visualized by confocal microscopy. (A) Reticulocytes were treated with FM 
1-43 and subsequently incubated at 37°C in the presence of AG-Tf. R, reticulocyte; E, 
erythrocyte; arrows, collocalized FM 1-43 and Tf. Scale bar is 5 Mm. (B) Huh7 cens 
were treated with FM 1-43 and then with AG-Tf, as in Panel A. In order to visualize the 
internalized dye, it was required to increase the photomultiplier tube gain to levels that 
elicit saturation of the dense, membrane signal surrounding these thin, adherent cens. 
Arrows indicate FM 1-43 vesicles that do not contain Tf. 
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monitored its intensity during endocytosis of diferric transferrin. Rhodamine B-[(2,2'-
bipyridin-4-yl)aminocarbonyl]benzyl ester (RDA) has been shown to accumulate in 
mitochondria, in a membrane potential-dependent manner, and to be quenched by ifOn 
(40). Live imaging was performed (as above) using AG-Tfto specifically label the 
endosomes. A rapid quenching of the mitochondrial signal was consistently observed 
when endosomes came into contact with mitochondria. The relationship between 
endosomal proximity and RDA quenching was determined by analyzing the red and 
green fluorescent signal intensities within a region of interest that included a 
mitochondrion and the X-Y plane in its immediate vicinity where an endosome 
approaches during the time series (Figure 2.7; Supplemetal Video 2.4). Since we were 
unable to monitor cells along the Z-plane and still maintain adequate time resolution, it 
was impossible to locate control mitochondria which we were confident did not interact 
with Tf-containing organelles. Nonetheless, we were able to verify that the cell remained 
within the same focal plane and that there was not an artificial drop in the overall signal 
for the duration of acquisition by monitoring the fluorescent intensity of a mitochondrion 
in which we do not observe contact with an endosome at the instant of contact within the 
primary region of interest (data not shown). 
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Figure 2.7 Endosome-mitochondria proximity increases chelatable, mitochondrial 
iron. 
(A) Representative confocal micrograph time series of a reticulocyte labe1ed with RDA 
(red) and AG-Tf (green). The arrow denotes a mitochondrion to which an endosome 
approaches, causing a quenching of the red fluorescence. The red organelle before the 
arrowhead represents a control mitochondrion that does not move out of focus or change 
fluorescence intensity during the segment. (B) Quantification of the intensities of the 
green and red signaIs within a region of interest including the mitochondrion indicated by 
the arrow, and the X-y space immediately surrounding it. Data was smoothed using a 
running average algorithm (sampling proportion = 0.100). 
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2.6 Discussion 
Developing red blood cells acquire and utilize iron at a remarkable rate. Due to 
iron's virtual insolubility and potential toxicity, the mechanism of transport ofiron in 
these cells requires specialized machinery that is stringently controlled. A proposed, and 
conventionally accepted, component of this system is a low molecular weight, 
cytoplasmic iron binding moiety. This intermediate would act as a chaperone, mediating 
transfer from the endosomal vesicle to the mitochondrion, the site ofheme biosynthesis. 
The idea of a LIP was tirst conceived in 1946 by Greenberg and Wintrobe (41) as weIl as 
by Ross (42), in the same year, both ofwhom used data from radiotracer experiments to 
determine that there was a "metabolic pool" of body iron that could be used for 
erythropoiesis, but was distinct from storage iron. After the discovery that transferrin is 
the principle physiological Fe donor, this concept was moditied by Jacobs, who 
speculated that a labile, low-molecular weight Fe intermediate was present in both 
erythroid and non-erythroid cells (24, 25). In spite ofthis, nearly 40 years after the 
conception of the LIP, the nature of this chelatable cellular Fe has still not been revealed. 
Interestingly, desferrioxamine treatment of iron overloaded patients willlead to the 
urinary excretion of ferrioxamine, while, when given to normal individuals, this drug will 
not lead to the excretion of Fe, indicating that the source ofiron for DFO is not a normal 
physiological pool (24). Furthermore, in vitro, membrane permeable chelators are able to 
bind iron from cultured cells, including reticulocytes, however the intracellular source of 
this Fe is, at best, vaguely identifiable in these studies (19, 29, 43); it is just as likely that 
chelators strip Fe from organelles or membrane components as from the cytoplasm. 
Renee, the so-called LIP has been defined by the amount of iron that the experimentor' s 
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chelator was able to bind. In the present study, we overcame this ambiguity ofusing 
permeant che1ators by resealing reticulocytes with HES-DFO and thus show that 
vesicular iron is not transported into the cytosol. 
Using electron microscopy, we demonstrate that transferrin-containing endosomes 
come into contact with mitochondria, while from fluorescence microscopy data we show 
that this contact results in an increase in che1atable mitochondrial iron. These transient 
contacts are very like1y to be dependent on the activity ofboth molecular motors and 
docking complexes. The recent discovery of the genetic mutation in the hemoglobin 
deficit (hbd) mouse (44, 45), whose reticulocytes demonstrate reduced transferrin cycling 
(46), further supports the notion that endosomal motility is necessary since the yeast 
homologue of the gene in question, Sec1511, is known to be involved in vesicular 
docking. We expect that myosin Yb is a major contributor to this movement, based on 
recent findings by Pro vance et al. (47). Previously, one could envisage a mechanism 
wher~by the vesicle would only have to form in order to allow the acidification of the 
microenvironment surrounding the Fe2-Tf complex and the reduction ofthe metal to Fe2+. 
This former mode1 would require little or no movement of the formed vesicle since the 
free and reduced iron would then exit the organelle and enter the "UP". Considering our 
results, the most attractive model for transfer of iron from endosomes to mitochondria is 
one in which a transient, yet intimate, relation between the two organelles facilitates a 
direct transfer ofthe metal, circumventing any free, cytosolic intermediary. 
The study described herein demonstrates that Fe, in the form of Tf, can be 
de1ivered to mitochondria without the necessity of a cytoplasmic, low molecular weight 
iron binding moiety, as previously considered. Our experiments were limited to erythroid 
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cens (i.e., reticulocyte) and, therefore, we cannot ignore the possibility that this pathway 
is unique to hemoglobin-synthesizing cells. This is not an unlikely prospect given that 
there have been profound differences, with regards to iron metabolism, demonstrated in 
such cens (15). The presence of a strong iron chelator in the cytosol of these cells had no 
effect on the incorporation of 59Fe2_ Tf into heme. It may be argued that there could still 
exist a cytoplasmic chaperone that tightly binds vesic1e-derived Fe and shuttles it to the 
mitochondria, thus shielding it from chelation by HES-DFO. This is unlikely, however, 
since when the Fe was delivered as Fe-SIH2, its incorporation into heme was effectively 
blocked by the cytosolic HES-DFO. One would expect that if a "labile" moiety that 
shuttled iron from the vesic1e existed and could bind iron more efficiently than HES-DFO 
(DFO has an affinity for iron of 10-33), it would be able likewise to sequester Fe from the 
Fe-SIH2 chelate. 
Microscopie analysis of the position of the Fe-containing vesic1es with respect to 
mitochondria clearly shows tha~ the endosomes do not simply enter the cell, rather they 
migrate deep below the plasma membrane and move extremely close to mitochondria. 
To the best of our knowledge, this is the first documented account oflive confocal 
microscopy oftransferrin-Fe uptake in reticulocytes. In most ofthe CUITent receptor-
mediated endocytosis models, transferrin has been shown or postulated to enter a sorting 
endosome, in which differing ligands are separated before continuing their divergent 
itineraries through the cell. To investigate wh ether other ligands enter reticulocytes, we 
labeled the plasma membranes of the ceUs with a fluorescent probe that targets 
membrane phospholipids (FM 1-43). In contrast to a hepatocyte-like cellline, which 
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clearly demonstrated intemalized vesicles devoid of AG-Tf, aIl of the endocytosed 
vesicles in the reticulocytes contained the transferrin. 
Thirty-seven years ago, Tf intemalization by immature erythroid cells was first 
proposed to be involved in iron acquisition (48) and it took another fifteen years or so to 
unequivocally demonstrate that Fe2-Tf complexes were acquired by receptor-mediated 
endocytosis (49-53). After the more than twenty years that have since e1apsed, the post-
endosomal path of iron remains totally enigmatic; the only mode1 that has ever emerged, 
is the one invoking an inscrutable "LIP" that allegedly serves as an intermediary between 
endosomes and mitochondria. The results reported here have challenged this concept by 
describing a mechanism ofintracellular Fe trafficking whereby Tf-containing endosomes 
cede their iron atoms directly to mitochondria. Importantly, this may be a paradigm for 
Fe trafficking in cells in general, since there is vast literature showing movement of Tf-
TfR-containing endosomes to various intracellular structures, such as Golgi complexes, 
endoplasmic reticulum and perinuclear structures (review~d in Kühn et al. (54), Ponka 
and Lok (55), and Maxfie1d and McGraw (56)). Unfortunately, virtually aIl ofthese 
studies employ Tf as a marker, not considering the actual function of the protein. Since 
the only known functions of Tf are the transport and delivery of Fe through the 
circulation and to cells, the movement ofTf-containing endosomes towards various 
intracellular structures is like1y related to iron delivery to these organelles. 
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Chapter 
3 
The Anemia of 'Hemoglobin Deficit' (hbd/hbd) Miee Is Caused by a 
Defeet in TransferrÏn Cyeling 
3.1 Preface 
In Chapter 2, we provided evidence implicating a direct interaction between 
endosomes and mitochondria in the transfer of iron from the former organelle to the 
latter. This interaction required the movement of endosomes and is like1y to involve the 
concerted roI es of a number of proteins that are responsible not only for the translation of 
the endosomal components, but also for the docking and communication between these 
organelles. Based on earlier reports, it seemed like1y that a defect in the intracellular 
handling of iron is manifest in the hemoglobin-deficit (hbd) mouse. Thus, in the 
following chapter, we explore the possibility that the endosomal contribution to iron 
delivery to mitochondrial ferrochelatase is aberrant in hbd reticulocytes, with the prospect 
that the recently identified, mutated protein (Sec1511) in these cells plays a significant 
role in the hypothesized "kiss and ron" paradigm. 
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3.2 Abstract 
The hemoglobin-deficit mouse mutant (hbd) is characterized by a hypochromic, 
microcytic anemia that is inherited in an autosomal, recessive manner. The recently 
identified gene responsible, SecJ 511, is specific to hematopoietic stem cells and is 
homologous to a gene encoding a member ofthe exocyst pathway in yeast. However, the 
defective cellular mechanism underlying the hemoglobin deficiency in hbd/hbd mice has 
not been functionally identified. Here we investigated the possibility that erroneous 
transferrin trafficking is responsible for the hbd phenotype. Reticulocytes were harvested 
from hbd/hbd mice and from background- and age-matched controls. Iron and transferrin 
uptake and iron utilization experiments were perfonned using 59Fe_ or 125I-transferrin to 
follow the trafficking and utilization of the protein and metal. Compared to controls, iron 
and transferrin uptake as well as iron incorporation into heme was compromised in hbd 
reticulocytes. Importantly, reduced heme synthesis in these cells was restored to nonnal 
values by using an iron source which bypasses the transferrin-receptor pathway. We also 
found that +/+ and hbd reticulocytes take up free, ferrous iron at identical rates, while the 
rates of Tf internalization and extemalization were significantly decreased in the mutant 
cells. Finally, utilization of endosomal radioiron was likewise deficient in the hbd 
reticulocytes. Our results indicate that heme biosynthesis, DMTl, and the mitochondrial 
iron handling machinery are aH nonnal in hemoglobin-deficit mice, while transferrin 
cyc1ing is deficient. Therefore, the product of SecJ 511 is directly involved in vesicular 
trafficking, docking, fusing, and/or cargo delivery in erythroid precursors. 
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3.3 Introduction 
In human physiology, iron (Fe) is not a trace element; the normal adult has four to 
five grams of iron in his or her body. Over two thirds of this metal is found in erythroid 
tissues as hemoglobin (Hb). Erythrocytes are being produced at a rate of about two 
million per second, requiring approximately 25 mg of Fe per day. Thus, the cells of the 
bone marrow must efficiently acquire and process serum Fe, which is almost entirely 
bound to transferrin (Tf), to keep pace with erythropoietic demand. 
Cells acquire diferric Tf by a receptor mediated endocytosis pathway, whereby 
the chelate binds to its cognate receptor (TfR) on the cell surface, a clathrin-coated pit 
forms, and the complex enters the ceIl, enclosed within a vesicle (1). When vesicular pH 
drops below 5.5, through the activity of a v-ATPase proton pump, iron is released from 
Tf and subsequently transported across the endosomal membrane by DMTI (2-4). 
Although sorne ofthe next steps have yet to be understood, it is known that the Fe 
. eventually arrives at the mitochondrial matrix where ferrochelatase, associated with the 
inner mitochondrial membrane, catalyses its insertion into protoporphyrin IX (PP IX) to 
formheme. 
The hemoglobin-deficit (hbd) mouse is characterized by a hypochromic, 
microcytic anemia, reticulocytosis, hyperferremia, and increased red cell free 
protoporphyrin (5-9). The defect was recently identified as an exon deletion in Sec1511, 
the mammalian homologue of a yeast gene which encodes a protein involved in the 
exocytic pathway (10, 11). Interestingly, the defect appears to be specific for erythroid 
tissues. It has previously been demonstrated that reticulocytes from hbd mice (henceforth 
referred to as "hbd reticulocytes") have decreased FeTfuptake, sufficient serum Fe, and 
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nonnal TtR levels. Additionally, we have recently shown that vesicular movement is 
necessary for efficient utilization oftransferrin-derived iron (12). Thus, the present study 
examines the possibility that the anemia of hbd mice is caused by a defect in the 
trafficking of FeTf. 
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3.4 Materials and Methods 
3.4.1 Materials 
59FeCh and Na1251 were purchased from ICN (Irvine, CA). a,a-dipyridyl (DP) 
was obtained from Fisher Scientific Co. (Fair Lawn, NJ). Salicylaldehyde isonicotinoyl 
hydrazone (SIH) was synthesized as previously described (13) and apo-Tf was loaded 
with 59Fe as previously described (14). Holo-Tfwas labeled with 1251 using Iodo-Beads 
(Pierce; Rockford, IL), according to the manufacturer's instructions. 59Fe_ 
salicylaldehyde isonicotinoyl hydrazone (59Fe-SIH) was generated by adding 59Fe-citrate 
(20: 1 molar ratio of citrate to 59FeCh) to two molar equivalents of SIH, dissolved in 50 
mM NaOH, to yie1d 25 !lM Fe-SIH in incubation medium and left for 60 min at room 
temperature. AlI other chemicals were purchased from Sigma (St. Louis, MO) unless 
otherwise stated. hbd/hbd mice were a generous gift of Dr. Michael Garrick. 
3.4.2 Reticulocyte Preparation 
Reticulocytes were harvested from phenylhydrazine treated mice by a previously 
described procedure (12) with sorne modifications. Briefly, reticulocytosis was induced 
in hbd/hbd or age-matched, background (C57BL/6) mi ce at similar ages by two 
intraperitoneal injections of neutralized phenylhydrazine of 40 mg/kg and 60 mg/kg on 
days 1 and 4 respective1y. Four days after the second injection (i.e., day 8), blood was 
extracted from the mice via cardiac puncture, into a heparinized syringe. The blood cells 
were washed twice with ice-cold PBS and a final time with MEM containing 25 mM 
HEPES, 10 mM sodium bicarbonate, and 1 % BSA ("incubation medium"). By new 
methylene blue staining, the celIs were determined to be comprised of 40-50% 
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reticulocytes (henceforth referred to as "reticulocytes"). InitiaIly, total RNA content was 
measured using orcinol reagent, as previously described (15), and used to normalize the 
amount of reticulocytes between the hbd samples and controls, to allay any discrepancy 
between the mean corpuscular volume of hbd versus control cells. However, by 
comparison to this method, it was determined that cell counting, using a hemocytometer, 
was a sufficiently accurate technique for equilibrating reticulocyte numbers between 
samples; therefore, the data are presented according to the cell counts. 
3.4.3 Measurements of Iron Parameters 
Serum iron, total iron binding capacity (TIBC), serum ferritin, and transferrin 
saturation were determined using a Hitachi 917 (Roche Diagnostics, Basle, Switzerland). 
3.4.4 Iron uptake and Heme Biosynthesis 
Reticulocyte samples were suspended in incubation medium tO,a hematocrit of 
approximately 15% and treated for an hour, on ice, in the presence of 10 !lM 59FeTfto 
first label the cell surface receptors. Endocytosis was initiated by placing the samples in 
a 37°C water bath and was stopped by retuming the samples to ice and simultaneously 
adding ice-cold PBS to the tubes, at the indicated time points. The cells were washed and 
the herne fraction was extracted using methyl ethyl ketone, as previously described (16). 
The heme and non-heme fractions were subsequently evaluated in an LKB 
Compugamma Counter (LKB Instruments, Pleasant Hill, CA). 
For Fe(II) (non-Tf Fe uptake), cells were incubated at 37°C in 0.27 sucrose, 
buffered by 4 mM PIPES at the indicated pH values, in the presence of 20 !lM 59Fe2+ for 
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one hour. The 59Pe2+ was prepared as previously described (17), using an ascorbate:iron 
ratio of 44: 1. A control experiment indicated that within one hour, 59Pe uptake under 
these conditions is linear (data not shown). Excess radioiron was removed by washing 
the cells with PBS containing 5 mM EDT A, and treating the cells with 1 mg / mL 
pronase for 30 min on ice, followed by washing in PBS. The remaining radioactivity in 
the samples was intemalized by the cells, since control samples containing only 
erythrocytes did not retain any radioactivity after the washing steps (data not shown). 
3.4.5 Mitochondrial Iron Uptake 
We treated reticulocytes with succinylacetone (SA), an inhibitor of 5-
aminolevulinic acid (ALA) dehydratase, to promote the accumulation of radioiron in the 
mitochondria (18). Briefly, cells were treated for 30 min. at 37°C in the presence of 1 
mM SA prior to being exposed to 59PeTf. After labelling, the cells were washed, lysed, 
and the stromal fraction isolated exactly as previously described (18). Samples that 
remained at 4°C after adding the 59PeTf served as controls for the amount of plasma 
memrane 59Pe was associated with the samples. 
3.4.6 Mitochondrial Iron Utilization 
Reticulocytes were treated with isoniazid (INB), an inhibitor of ALA synthase, to 
promote the accumulation ofradioiron in the mitochondria (19,20). Briefly, cells were 
treated for 30 min. at 37°C in the presence of20 mM INB prior to being exposed to 
59PeTf for 1 br (37°C). After thorough washing to remove the INB, cells were warmed to 
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37°C in incubation medium for the indicated time intervals. The herne fraction was 
separated as described above. 
3.4.7 Iron Chelation 
Samples were prepared in parallel: for the measurernent of iron incorporation into 
herne (see above) and for the measurement of chelated iron for each chelator. The 
chelator, either 100 !lM SIR or 1 mM DP, was added to the samples 30 min. before the 
addition of 59FeTf, while the samples were being held at 4°C. After incubating thern with 
radioiron for the indicated time intervals, the cells were washed 3 times in ice-cold PBS 
and lysed in about 10 volumes of distilled water. To extract the chelator-bound fraction, 
about six volumes of co Id (-20°C) ethanol were added to the lysates, which were then left 
for 2 hours at -20°C to accelerate protein precipitation. Finally, the samples were 
centrifuged (about 900 x g at 4°C) and the pellet (protein associated 59Fe) and the 
supematant (chelator bound 59Fe) separately counted in the gamma counter. 
3.4.8 Transferrin Cycle 
Uptake: l25I-Tf was added to prewarmed (37°C) reticulocyte sampI es to a final 
concentration of 2 !lM. At the indicated time intervals, endocytosis was halted by 
transferring the sampI es to ice-cold PBS. Surface-bound transferrin was removed by 
pronase treatment and washing (see above), and the intemalized 1251_ Tf quantified by 
gamma counting. 
Release: The samples were loaded for 60 min. with 2 !lM 125I_Tf(as above) and 
the free 125I-Tfremoved by washing the samples three times with ice-cold PBS. The cells 
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were then resuspended in incubation medium containing 2 !lM unlabeled Tf and 
incubated for the indicated time intervals at 37°C. Endo-/exo-cytosis was halted by 
placing the samples in ice-cold PBS. The cells were centrifugated and both the cell pellet 
and supematant (Tf release) retained for gamma counting. 
3.4.9 Data Analysis 
For aU data herein, the average of duplicate samples is presented. Each 
experiment was repeated at least four times and representative results are presented. 
"Day-to-day" variability and logistical constraints generally precluded sophisticated 
statistical analysis, however, the deviation in relative changes between replicate 
experiments was typically below 3%. To compare the differences in Tf cycle time, we 
determined the tY2 for uptake or release of J25I_ Tf for each experiment, averaged the value 
between trials, calculated the standard deviations, and established significance using 
Student's t-test to generate the p-values. 
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3.5 Results 
Measurements ofblood iron indices revealed that, compared to age-matched 
background mi ce, the hbd mice had slightly elevated serum iron levels (Table 1). While 
storage iron appeared normal, as inferred from the serum ferritin levels, Tf saturation was 
elevated in these mice (69±7% versus 43±12% in controls). These results may reflect 
increased Fe absorption as a result ofthe anemia. 
Table 3.1 Serum iron parameters in +/+ and hbd/hbd mice (mean ± SD) 
Parameters 
Ferritin (llglL) 
Serum iron (Ilmol/L) 
TIBC (Ilmol/L) 
Tf saturation (%) 
+/+ mice 
(n = 9) 
418±51 
26±6 
60±7 
43 ± 12 
hbd/hbd mice 
(n= 8) 
441 ± 99 
39± 4 
56±2 
69± 7 
As expected, both iron uptake and the incorporation of Fe into heme in hbd 
reticulocytes was greatly compromised; about 30% of controls (Figure 3.1). 
Interestingly, the decrease in Fe uptake was not proportionate in the two fractions; the 
percentage of cell associated, non-heme Fe was dramatically increased in hbd 
reticulocytes. This is probably because the levels ofTfR are still normal in the mutant 
cells, thus permitting a similar amount of surface binding of 59FeTf. 
To determine whether DMTI activity may be decreased in the mutated ceIls, 
ferrous ascorbate, an Fe(II) source, was added to control and hbd reticulocytes at varying 
pH values. Somewhat surprisingly, there was no significant change in Fe uptake when 
the pH was lowered from physiological pH to as much as 6.0 (Figure 3.2). This result is 
consistent with a recent finding that DMTI is still able to efficiently transport iron in the 
115 
9 
-
8 (fJ 
f 7 
:3 6 (.) 
'';:::; 
~ 5 
(0 
0 4 ji 
0 3 E 
~ 2 Q) 
u. 
Cl 1 \1) 
0 
0 15 30 60 
• home _59Fe 
non-heme - 59Fe 
o 15 30 60 
Incubation time (mins) 
~ ____________ --JI ~I ______ ~ ____ --~ 
+1+ hbdlhbd 
Figure 3.1 Reticulocytes from hbdlhbd mice have impaired holo-Tf uptake. 
Wild-type or hbd reticulocytes were incubated at 37°C for the indicated time intervals in 
the presence of 10 llM 59FeTf. After washing out unbound radioactivity, the herne and 
non-heme fractions were isolated, the radioactivity counted, and the amount of iron per 
million reticulocytes calculated . 
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Fi~ure 3.2 Fe2+ uptake by hbd reticulocytes is normal. 
Fe + uptake by +/+ or hbd/hbd reticulocytes was determined by treating the cells, at 37°C 
and at the indicated pH values, with 20 llM ferrous ascorbate for 60 min. Total cellular 
radioactivity was determined by washing out unbound 59Fe2+ and gamma counting of the 
samples. 
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absence of a proton gradient (21). There was also no significant difference between hbd 
reticulocytes and controls. It is important to note that uptake of Fe(II) by these cells was 
considerably more efficient than by the Tf/TfR pathway, indicating that DMTl is not 
limiting physiological iron uptake. 
After Fe is exported from the endosome by DMTl, it must somehow enter 
mitochondria. Therefore, we examined whether mitochondrial handling ofTf-derived Fe 
was decreasing Fe utilization in hbd reticulocytes. Treatment of reticulocytes with 
succinylacetone, an inhibitor of ALA dehydratase (the second enzyme in the heme 
synthesis pathway), will cause an accumulation ofiron in mitochondria (18, 22). When 
we incubated hbd reticulocytes with 59FeTf in the presence of succinylacetone, compared 
to controls, there was no significant difference in the percentage of cell-associated 
radioactivity that appeared in the mitochondrial fraction (Table 2). However, the samples 
that were not treated with the inhibitor did exhibit a decreased proportion of the radioiron 
in their mitochondria. This .is likely due to the decrease in the ability of the cells to 
acquire Fe, and, consequently, deliver it to mitochondria, while simultaneously having 
the ability to efficiently synthesize heme from the available iron. 
Table 3.2 Percentage of stromal 59Fe with or without SA treatment 
Incubation +/+ reticulocytes • hbd/hbd reticulocytes· 
Time (min) ------------------------------------ --------------------------------
-SA +SA -SA +SA 
15 49 73 30 78 
30 37 78 23 78 
60 25 75 15 78 
*Stromal 59Fe as % oftotal cell-associated 59Fe. 
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Another part of the Fe utilization pathway that is a candidate for the defect in the 
hbd mice is that ofheme biosynthesis. This seems unlikely, since either a sideroblastic or 
porphyric phenotype would be expected were the porphyrin synthesis pathway deficient. 
Nonetheless, we tested the integrity ofheme biosynthesis by supplying the cells with 
59Fe-SIH, a membrane permeable iron chelate that has the ability to supply Fe for 
ferrochelatase (23-25). Again, there was no significant decrease in iron incorporation 
into herne when the Tfuptake pathway was bypassed in this way (Figure 3.3). 
Additionally, mitochondria were loaded in these cells by pre-treating them with INH, 
which inhibits ALA synthase, and then with 59FeTf. Like that with succinylacetone, this 
treatment is known to lead to the accumulation of iron in the mitochondria, even though 
porphyrin synthesis is disrupted (20). Removal of the inhibition by washing out INH will 
permit the utilization of the 59Fe for herne biosynthesis (19, 20). Figure 3.4 shows that 
there is no decrease in the synthesis ofheme in hbd reticulocytes with 59Fe-Ioaded 
mitochondria, compared to control s, indicating again t~at heme biosynthesis is normal in 
these cells. 
In our previous study, we demonstrated that the quantitative amount of 
transferrin-derived 59Fe that ferrochelatase inserts into PPIX is virtually equivalent to the 
amount that is chelatable with membrane permeant chelators, namely SIH and 2' ,2' -
dipyridyl (DP) (12). Here, we tested whether these chelators were able to intercept 
radioiron in hbd reticulocytes. There was no difference between the mutant reticulocytes 
and controls; in both cases, the same amount of iron that was used to form herne was 
chelated by either compound (Figure 3.5). 
118 
Since DMTl activity, heme biosynthesis, mitochondrial Fe handling, TiR, iron 
absorption, and the delivery of Fe to the chelatable pool are an normal in hbd mi ce, we 
examined whether there was a defect in Tf cycling in their reticulocytes by incubating the 
cens with 1251_ Tf. As shown in Figure 3.5, there is a very large lag in both the 
intemalization ofholo-Tf and the extemalization ofTfin the hbd reticulocytes when 
compared to controls. The tY2 for Tf intemalization in mutants was 11.90 ± 0.63 min, 
about double that ofwild type reticulocytes (5.08 ± 0.78;p < 0.001). The kinetics of Tf 
release from cens closely matched those ofuptake (11.62 ± 0.87 versus 4.60 ± 0.42; P < 
0.001), indicating an equilibrium was apparent for Tfuptake and release. These data 
indicate that the defect in the hemoglobin deficit mice directly affects the trafficking of 
transferrin in erythroid tissues. 
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herne synthesis in hbd reticulocytes. 
Cells, wild type or hbd, were incubated for 60 min in either 10 !lM 59F eTf or 100 !lM F e-
SIH. The heme fraction was extracted and measured in a gamma counter. Total amount 
of radioactive heme per million reticulocytes was calculated. 
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Figure 3.4 Mitochondrial Fe is used norrnally by hbd reticulocytes. 
After 1abelling control or mutant cells with 59FeTfin the presence of20 mM INH, to load 
the mitochondria, reticu10cytes were sufficiently washed, to remove the INH, and 
subsequently incubated at 37°C for one hour. The percentage of total, cell-associated Fe 
in heme was calculated after the heme and non-heme fractions were separated and 
measured in a gamma counter. 
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Figure 3.5 Transferrin cycling is disturbed in hbd reticulocytes. 
(A) Tf uptake: Wild-type or hbd reticulocytes were incubated in the presence of 2 /lM 
1251_ Tf for the indicated time intervals, placed on ice to haIt vesicular trafficking, and 
treated with pronase to remove the surface-bound radioactivity. The cens were then 
washed and measured in a gamma counter. Data is shown as the amount of radioactive 
Tf per million cells. (B) Tf release: Cells that had been labeled for 60 min as in A were 
washed and incubated in the presence of2 /lM 56FeTffor the indicated times. Release 
was deterrnined by the amount of radioactivity rernaining within the cens at the time of 
incubation and expressed as a percentage of the total amount of radioactivity in the cens 
before the final incubation step. 
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3.6 Discussion 
The first description of the hemoglobin-deficit mouse was made in 1969 by 
Scheufler (5). These mice have a hypochromic and microcytic anemia, hyperferremia, 
reticulocytosis, and elevated erythrocyte protoporphyrin levels. Scheufler' s findings, and 
those of others (6-9), suggest that the defect is related to iron acquisition and is exclusive 
to the hematopoietic system. These mi ce have normal transferrin receptor levels, yet 
exhibit profoundly deficient iron uptake (7). In the present study, after confirming that 
hbd reticulocytes have compromised iron uptake, we have dissected the pathway through 
which iron is acquired by erythroid cells and incorporated into PPIX to form heme, in 
order to reveal the mechanism responsible for the defect in these animaIs. 
Our initial results verify previous findings that there is a modest increase in 
plasma iron levels in hbd mi ce (6). We speculate that this reflects an increase in 
nutritional iron uptake in response to anemia by the, as yet hypothetical, "erythroid 
regulator". lronically, serum ferritin levels were normal, suggesting that hepatic iron 
stores were normal; it would be expected that an anemic mouse with normal iron 
absorption would develop an iron overloaded phenotype. It has recently been 
demonstrated that the circulating levels ofhepcidin, an antimicrobial peptide, secreted by 
the liver and known to decrease dietary iron absorption, is regulated by serum iron levels 
(26-28). Thus, the intestine may be receiving conflicting signaIs from the "erythroid 
regulator" and the "stores regulator" when the erythron is unable to clear circulating 
transferrin iron. In support of this, Wilkins et al. (29) have recently shown hepcidin 
levels to be elevated in hbd mice. Thus it is likely that another factor is communicating 
122 
the erythropoietic demand for iron to the gut, and perhaps reticuloendothelial system, and 
that the hepcidin signal overrides this "erythroid regulator". 
We have previously demonstrated that the endosome has a significant role in 
directing iron to the mitochondria in reticulocytes (12). Our CUITent results support this 
daim since here we demonstrate that an erythroid-specific factor, when defective, 
interferes with the availability ofvesicular Fe for heme synthesis. Two independent 
groups (10, Il) have simultaneously identified the defect as being caused by the rernoval 
of an exon from the Secl51I gene. The yeast homolog of the SEC 15L 1 protein is an 
integral member of the exocyst, a complement of proteins which orchestrate transport of 
secreted material from the Golgi, likely involved in vesicular fusion (30, 31). Andrews' 
laboratory hypothesized that the hbd mutation leads to premature exocytosis of Fe-
containing vesic1es, thus reducing iron bioavailability in the cells (10). Our results are in 
conflict with their proposaI since we observed a decrease in 1251_ Tf cyding in hbd 
reticulocytes; it is more likely that the consequences of Secl511 mutation involve a 
reduction in the efficiency ofvesicular trafficking, docking, fusing, and/or cargo delivery, 
as White et al. put forward (11). Furtherrnore, since we observe a balance ofTfuptake 
and release in affected cells, albeit compromised, we hypothesize that regulatory 
mechanisms are in place in cells so as to conserve plasma membrane and surface TfR, 
thus coordinating endocytosis with exocytosis. An alternative, though unlikely, 
possibility is that the mutation affects the two pathways similarly, causing an equivalent 
abrogation of endocytosis and exocytosis. 
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Chapter 
4 
Non-Herne Induction Of Herne Oxygenase-l Does Not Alter Cellular 
Iron Metabolisrn 
4.1 Preface 
The following chapter examines the effects on the induction ofheme oxygenase 
on iron metabolism in the cell. Herne oxygenase is responsible for the release of iron 
from herne and thus is an integral component of the intracellular handIing of iron. Hence, 
while the previous two chapters dealt with the handIing of iron by cells in uptake 
pathway, this chapter will focus on an aspect of the release pathway of iron. As HO-l 
has recently been ascribed to a major protective role discrete from its part in organismal 
iron homeostasis, the following investigation examines the possibility that the 
recruitment ofheme oxygenase for protective purposes operates through an alternative 
mechanism which do es not involve the catabolism of copious amounts ofheme iron, 
thereby preserving normal cellular iron distribution. 
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4.2 Abstract 
The catabolism ofheme is carried out by members of the heme oxygenase (HO) 
family. The products ofheme catabolism by HO-l are ferrous iron, biliveridin 
(subsequently converted to bilirubin), and carbon monoxide (CO). In addition to its 
function in the recycling ofhemoglobin iron, this microsomal enzyme has been shown to 
protect cells in various stress models. HO-l can be induced not only by heme, but also 
by cytokines, heat shock, metals, and other cellular stressors, especially those that 
generate reactive oxygen species (ROS). Implicit in all the reports ofHO-l 
cytoprotection to date are effects on the cellular handling ofheme/iron. However, the 
limited amount of uncommitted heme in non-erythroid cells brings to question the source 
of substrate for this enzyme in non-hemolytic circumstances. In the present study, HO-l 
was induced by either sodium arsenite (ROS producer) or hemin in the murine 
macrophage-like cellline, RA W 264.7. Both ofthese inducers eHcited an increase in 
activ~ HO-l, however only hemin exposure induced an increase in the synthesis rate of 
the iron storage protein, ferritin. This effect ofhemin was the direct result of the 
liberation ofiron from heme by HO. Our results suggest that iron released from hernin 
by HO-l stimulates ferritin synthesis via the classical, post-transcriptional, iron 
regulatory protein/iron responsive element system, while an increase in the enzyme by a 
non-herne inducer does not lead to iron release from endogenous herne. 
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4.3 Introduction 
In the average adult, at equilibrium, approximately 2 million red blood cells 
(RBCs) are being tumed over every second. In a day, this process requires about 25 mg 
of iron (Fe) to be recyded from the hemoglobin of effete erythrocytes. Herne oxygenase 
1 (HO-l) is the enzyme responsible for catabolizing the heme from senescent RBCs to 
release Fe, as well as equimolar amounts of carbon monoxide (CO) and biliverdin, for its 
eventual reuse in erythropoiesis. Another, non-inducible isoform ofheme oxygenase, 
with similar heme catabolic properties as HO-l, HO-2 is present in substantiallevels 
primarily in the central nervous system and testes (1, 2). Although the heme degrading 
function of HO has been known since the 1960's (3, 4), only recently has it been shown 
that heme oxygenas es may be involved in cytoprotection against cellular stresses (for 
review see Camara and Soares (5), Abraham and Kappas (6), Otterbein et al. (7), Ryter et 
al. (8)). This newer discovery ofthe enzymes' potential as a tissue defence mechanism 
has spawned a flurry of studies. by nUmerous groups who have shown by several different 
approaches that induction or overexpression ofheme oxygenase 1 can protect tissues 
from various insults, induding oxidative stress and immune system attack. 
The precise mechanism by which HO-l mediates its protective function remains 
controversial. Breakdown ofheme being the only known reaction catalyzed by the 
enzyme, extensive research has alleged that one or more of the reaction products 
mediate(s) this feature of HO-l. Biliverdin, besides having sorne intrinsic antioxidant 
properties, is rapidly converted to bilirubin by biliverdin reductase (BVR), and is 
believed to redox cyde in the presence ofBVR and antioxidants to reduce reactive 
oxygen species (9). In addition, bilirubin possesses antioxidant activity (10). Carbon 
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monoxide, which is chemically very similar to nitrogen monoxide (NO) (11), can bind to 
the herne groups in various proteins to modulate their function. By this property, it has 
been shown that CO may initiate intracellular signalling cascades related to cell survival, 
mimicking the effects ofHO-1 induction (2,5, 12, 13). Finally, when heme is provided 
to cells, the generation of Fe via the HO-l catalyzed reaction induces ferritin (Ft; 
ubiquitous iron storage protein) synthesis (14), which Ferris et al. demonstrated to 
decrease reactive oxygen species within cells by sequestering catalytic iron (15). 
Probably the most enigmatic concem regarding the mechanism by which HO-l protects 
tissues is the source of substrate for the enzyme. Over 95% of the body' s herne is found 
in hemoglobin and myoglobin (16). Considering the relative contribution of the heme 
compartments to body mass, there are about 97,900 mg heme / kg tissue in the 
hernoglobin compartment (mostly comprised of erythrocytes), 120 mg heme / kg tissue in 
the myoglobin compartment, and only 27 for that of aIl other compartments combined 
(subtracting bone mass from the remaining body weight) (16, 17) (Table 1). 
Table 4.1 Distribution of heme in man (values compiled from Snyder et al. (17) and 
Bothwell et al. (16» 
Thus, it becomes apparent that, outside hernolytic conditions, there is a limited amount of 
herne available for HO-l to catabolize into the implicated cytoprotective reaction 
products. In fact, it has been estimated that cellular "free herne" is likely to be at 
concentrations lower than 30 nM (18). 
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In the CUITent study, we compare the effects of HO-l induction by hemin and a 
non-heme inducer (sodium arsenite) on iron metabolism in RA W 264.7 (macrophage-
like) cells to investigate whether elevated HO-llevels affect cellular iron metabolism. 
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4.4 Materials and Methods 
4.4.1 Materials and cel/Unes 
Unless specified otherwise, aIl reagents were purchased from Sigma (St. Louis, 
MO). 
RA W 264.7 cells were purchased from the American Type Culture Collection 
(Manassas, VA) and grown at 37°C in 75 cm2 culture flasks (Life Technologies, 
Burlington, Canada) in a humidified atmosphere of 5% CO2 and 95% air in DMEM 
(Wisent, St. Bruno, Canada) supplemented with 10% fetal bovine serum, L-glutamine 
(300 Jlg/mL), pyruvate (110 Jlg/mL), penicillin (100 U/mL), and streptomycin (100 
Jlg/mL). This media composition is referred to as "full media". 
Anti-HO-l antibodies were from Stressgen Bioreagents (Victoria, Canada). 
Plasmid containing fulliength rat HO-l cDNA was generously given to us by Dr. S. 
Shibahara. 35S-metabolic labelling kit and 59Fe (as ferric chloride) were obtained from 
Perkin Elmer (Boston, MA). Rabbit anti-Ft antibodies were from Roche (Indianapolis, 
IN). Hernin and Sn-protoporphyrin IX were purchased from Frontier Scientific (Logan, 
UT). 
Salicylaldehde isonicotinoyl hydrazone (SIH) was synthesized by us as previously 
described (19). 59Fe-hemin was generated by incubating reticulocytes, harvested from 
phenylhydrazine-treated mice (20), with 3 JlM 59Fe-transferrin C9Fe2-Tf; labelled as 
reported previously (21)) ovemight. The herne (readily oxidized to hernin) was extracted 
from the cells according to the method of Labbe and Nishida (22). Purity of the 59Fe_ 
hemin was confirmed by normal phase TLC analysis (standard silica plate; benzene, 
methanol, and 88% formic acid in a 8.5:1.5:0.13 ratio) against commercially available 
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hemin. The TLC plate was subjected to autoradiography to verify that the only form of 
radioiron was that in hemin. 
4.4.2 Induction and measurement ofHO-l 
RA W 264.7 cells were seeded in full media 24 hours prior to HO-1 induction. 
Hernin solution was prepared by first dissolving hemin chloride powder in 0.15 N NaOH, 
followed by a 10 times dilution in 0.15 M Tris-HCl, pH 7.0. This solution was added to 
the cells in full media to achieve a 5 !lM hemin concentration. For non-herne induction 
of HO-l, sodium arsenite, dissolved in distilled water, was used in one oftwo ways: 1) 
Full media was removed from the cells before the addition of 20 !lM sodium arsenite in 
DMEM, without supplemental serum. The cells were incubated for 60 min, washed, and 
the conditioned media from before the sodium arsenite treatment was returned. We have 
regarded the time at which we replace the media as t=1. 2) the sodium arsenate was 
added to the cells in full media to a final concentration of 3 !lM. This alternative protocol 
allowed us both to reach comparable levels ofHO-l protein as with 5 !lM hemin 
treatment and to leave the arsenite present for the incubation period, thus more c1ose1y 
mimicking the conditions of the hemin-treated samples. HO-l mRNA and protein levels 
were determined by northern blotting (fulliength HO-I cDNA probe) and western 
blotting, respectively. 
4.4.3 Measurement of ferritin synthesis rate 
Cells were labeled for lh with (100 !lCi/mL) [35S]-methionine in methionine-free 
DMEM, washed three times with cold PBS, after which they were lysed with RIPA 
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buffer (50 mM Tris-HCl, 150 mM NaCI, 1 % Nonidet P-40, 0.5% sodium deoxycholate, 
0.1 % sodium dodecyl sulfate (SDS» for 30 min at 4°C. Anti-ferritin antibody was added 
to the lysates which were incubated ovemight at 4°C, then 60 /JI of a 50% (v/v) 
suspension of protein A sepharose was added for 3 h at 4°C to precipitate the immune 
complexes. The beads were washed three times with cold RIPA buffer and then boiled 
with SDS loading dye. Immunoprecipitated protein was resolved by using 12.5 % SDS-
PAGE. The gel was dried and analyzed by autoradiography. 
4.4.4 Iron regulatory protein binding activity assay 
Iron regulatory protein (IRP) binding was determined using a band shift assay as 
described previously (23). Briefly, 5-10 million cells were washed with ice-cold 
phosphate-buffered saline and lysed at 4 oC in 80 /JI oflysis buffer (10 mM HEPES, pH 
7.5, 3 mM MgCI2, 40 mM NaCI, 5% glycerol, 1 mM dithiothreitol, and 0.2% Nonidet P-
40). After lysis, the sampI es were centrifuged for 5 min at 10,000 x g to remove the 
nuclei. Samples of cytoplasmic extract were diluted with two volumes of lysis buffer 
without Nonidet P-40 to a protein concentration of 1 /Jg//JI, and 10 /Jg aliquots were 
analyzed for IRP binding by incubating them with an excess amount of 32P-labeled 
pSRT-fer RNA transcript, which contains one iron responsive element (IRE) (24). This 
RNA was transcribed in vitro from linearized plasmid template using T7 RNA 
polymerase in the presence ofe2p] UTP. To form RNA-protein complexes, cytoplasmic 
extracts were incubated for 10 min at room temperature with excess amount oflabeled 
RNA. Heparin (5 mg/mL) was added for another 10 min to prevent non-specifie binding. 
RNA-protein complexes were analyzed in 6% nondenaturing polyacrylamide gels. In 
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parallel, duplicate samples were treated with 2% ~-mercaptoethanol before the addition 
of the RNA probe, to reveal the totallevels of IRP 1. 
4.4.5 Degradation of exogenous hemin or endogenous heme 
Exogenous hemin: RA W 264.7 cells were incubated in the presence or absence of 
3 llM sodium arsenÏte for 6 hr, followed by treatment with 50 llM 59Fe-hemin for 1 hr. 
Endogenous heme: RA W 264.7 cells were incubated in the presence of 1 llM 59Fe_ 
transferrin. After three days, the cens were washed and treated with or without 3 llM 
sodium arsenite for 6 hours. 
Herne and non-herne fractions were isoloated by washing the cens and then 
perfonning a previously described acid lysis and trichloroacetic acid precipitation method 
(25). The radioiron in each fraction was evaluated by counting in a Cobra II gamma 
counter (Packard Instruments; Meriden, CT). 
4.4.6 Data analysis 
An of the data presented are representative of at least three identical experiments. 
Error bars represent standard deviations. 
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4.5 Results 
4.5.1 Heme or sodium arsenite induce HO-1 expression in RAW 264.7 ceUs 
In order to establish a reliable HO-l induction protocol, we treated RA W 264.7 
cells with hemin or sodium arsenite and measured both HO-1 mRNA expression and 
protein levels by northern and western blotting, respectively. We observed a rapid 
increase in HO-1 mRNA levels within one hour oftreatment with 20 ~M sodium 
arsenite, that decreased back to baseline levels within 12 hrs (Figure 4.1 A). Treatment 
with 5 ~M hemin 1ed to a more sustained elevation ofHO-1 mRNA 1evels, since hemin 
was allowed to remain in the media throughout the time period, whereas exposure to 
sodium arsenite was only a 1 hr pulse (Figure 4.1A). Protein levels rapidly followed the 
increased message levels, the most robust expression apparent around 12 hours for both 
hemin or sodium arsenite (Figure 4.1Bi). In an alternative induction procedure, we 
determined that a continuous treatment with 3 ~M sodium arsenite or a 6 hr incubation 
with 5 ~M he~in yielded similar HO-1 protein levels (Figure 4.1 Bii). 
4.5.2 HO-1 induction by heme, but not sodium arsenite, induces an increase inferritin 
synth esis 
When intracellular, chelatable Fe levels rise, ferritin synthesis is activated in order 
for cells to store the excess of the metal. Additionally, it has been demonstrated that HO-
1 induction in the presence ofhemin will increase Ft levels via increased iron liberation 
from the metalloporphyrin (14). However, it remains uncIear whether increases in HO-1 
in the absence of exogenous hemin willlead to iron liberation and subsequent increases 
in Ft synthesis. Therefore, we treated RA W 264.7 cells with either hemin (5 ~M, 
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continuously) or with sodium arsenite (20 /lM, one hour pulse) and measured the rate of 
ferritin synthesis by metabolic labelling and immunoprecipitation. (In general, the heavy 
[21 kDa] and light [19 kDa] chain Ft subunits can be resolved on the polyacrylamide gel, 
however in sorne gels the two bands overlapped.) Figure 4.2 shows that hemin treatment 
led to a robust increase in ferritin synthesis that reaches a maximum around 6 hr and 
decreases to slightly elevated levels by 12 hr' In contrast, incubation ofthe ceUs in the 
presence of sodium arsenite had no effect on ferritin synthesis rate. Nearly identical 
results were obtained when NIH-3T3 cells were used under similar conditions (data not 
shown). 
4.5.3 Iron releasedfrom hemin by heme oxygenase activity causes the increase inferritin 
synthesis rate 
To determine whether the effect ofhemin on Ft synthesis that we observed was 
dependent on heme oxygenase activity, we preincubated the cells in the presence of the 
heme oxygenase inhibitor, tin protoporphyrin IX (SnPP) before adding hemin. In the 
absence ofhemin, a significant amount of Ft synthesis was apparent and was slightly 
Figure 4.1 Sodium arsenite treatment increases HO-1 rnRNA levels (previous page) 
A. RA W 264.7 ceUs were treated for one hour without (-) with (+) or 20 /lM sodium 
arsenite as described in Experimental Procedures. After the indicated times, RNA was 
extracted and subjected to electrophoresis and northern blotting with a full-Iength HO-I 
cDNA probe. The lower panel shows the agarose gel after staining with ethidium 
bromide, to demonstrate equalloading. B. RA W 264.7 cells were treated with (i) 20 /lM 
sodium arsenite for one hour and allowed to recover for the indicated times or with 5 /lM 
hemin for the indicated times; or (ii) for six hours with the indicated concentrations of 
hemin or sodium arsenite and the protein extracted by chemical detergent lysis. Equal 
amounts (30 /lg) of protein were subjected to denaturing, polyacrylamide gel 
electrophoresis (SDS-PAGE), blotted to nitrocellulose, and probed with anti-HO-l 
primary antibody followed by an alkaline phosphatase-conjugated secondary antibody. 
Coomassie blue staining is shown (ii) to demonstrate equal protein loading. 
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Figure 4.2 Induction of HO-l by sodium arsesnite does not affect Ft synthesis. 
CeUs were incubated for the indicated intervals with hemin or sodium arsenite and then 
with 35S-methionine for one hour. The ceUs were then lysed and the lysates probed with 
an anti-Ft antibody. Immune complexes were puUed down using protein A-sepharose 
beads and then subjected to SDS-P AGE, foUowed by autoradiography of the dried gels. 
H, ferritin heavy chain; L, ferritin light chain. 
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inhibited by SnPP treatment (Figure 4.3A), likely indicating that HO inhibition interferes 
with baseline levels of endogenous heme catabolism. When the cells were treated with 5 
~M hemin after (and in the presence of) the inhibitor, a significant, concentration 
dependent decrease in Ft synthesis rate was apparent. Additionally, when the highly 
permeant iron chelator, SIH, was present (100 ~M; in the absence ofSnPP), the level of 
Ft synthesis was barely detectible either in the presence or absence ofhemin. Together, 
these data show that iron released via heme oxygenase causes the elevated Ft synthesis 
when cells are exposed to hemin (Figure 4.3B). 
4.5.4 Heme oxygenase-dependent release ofironfrom hemin causes a decrease in IRP 
activity 
Acute ferritin protein upregulation is controlled primarily by a post-transcriptional 
mechanism involving the inactivation ofiron regulatory proteins (IRPs) which block 
translation of the ferritin mRNA by binding to a stem-Ioop structure on the 5'-
untranslated region of the message known as an iron responsive element (IRE). IRP 
binding activity can be measured by electrophoretic mobility shift assay. Thus, we 
determined the IRP binding activity in our sampi es to verify that iron released from 
hemin by HO was responsible for the increases in Ft synthesis that we observe. As 
illustrated in Figure 4.4A, hemin treatment causes a considerable decrease in both IRPI 
and IRP2 activities, while sodium arsenite treatment had no effect. This inhibition of IRP 
binding is abrogated in a concentration dependent manner if cells are pretreated with 
SnPP as shown in Figure 4.4B. By northem blotting, using a Ft heavy chain probe, we 
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Figure 4.3 Iron released from berne by HO-l induces Ft syntbesis. 
Cells were pretreated with the indicated concentrations of SnPP or 100 !lM SIR for 30 
min before 5 !lM hemin was added. Cells were then incubated for 6 hr, after which 
ferritin synthesis was assayed as in Figure 4. 2. In this figure the ferritin heavy (R) and 
light (L) chains migrated as a single band. 
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determined that there was no contribution of transcriptional regulation to the increase in 
Ft levels by hemin (Figure 4.4C). 
4.5.5 HO-l induction by sodium arsenite has no effect on endogenous heme levels 
Although we observe no evidence that HO-l induction by sodium arsenite 
releases Fe from heme in the absence of exogenous substrate, there remain the 
possibilities that Ft synthesis rate changes below our measurement sensitivity or that the 
smaIl amount of released iron is rapidly sequestered in the already present Ft. For this 
reason, we performed experiments to determine whether endogenous heme levels are 
decreased when HO-llevels are elevated. In order to label aIl of the heme in RAW 
264.7 ceIls, we grew the cells in the presence of 1 flM 59Fe2-Tffor three days. Control 
cells contained about 6.5% oftheir cell-associated radioactivity in heme (Figure 4.5B). 
Treatment with sodium arsenite had no effect on this value. A control experiment was 
performed in which exogenous 59Fe-hemin was applied to RA W 264.7 cells, with or 
without sodium arsenite treatment, confirming that the chemical induction of HO will 
lead to the catabolism ofheme if it is exogenously available for the enzyme (Figure 
4.5A). 
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4.6 Discussion 
Overwhelming evidence supports that HO-1 perfonns a protective role in the face of 
various cellular insults (5-7). However, the mechanism through which it executes this 
function remains unknown. In certain pathophysiological conditions, damage to tissues, 
namely erythrocytes or muscle tissue, leads to release of copious amounts ofhemoprotein 
which can then supply substrate to herne oxygenase in the affected tissues. Hemoglobin, 
when free in the plasma, will become oxidized to methemoglobin, which can readily 
abdicate its heme moiety (26, 27). Although plasma hemoglobin and heme binding 
proteins, such as haptoglobin, hemopexin, and albumin, are able to prevent the liberation 
and toxicity ofheme, excessive release ofhernoprotein will presumably saturate these 
buffering systems, allowing heme to enter endothelial cells. This is the case in 
rhabdomyolysis, a disease in which Nath et al. have demonstrated that HO-I induction 
provides protection to tissues presumably through the subsequent increases in Ft and 
bilirubin (28). Ischemia~reperfusion in jury will also bring about significant intravascular 
hemolysis (29, 30), again supplying substrate for HO. In these cases, the detoxifying 
Figure 4.4 Induction of Ft synthesis by hemin-derived iron is via IRE-IRP, post-
transcription al regulation. (previous page) 
A. After 6 hr of continuous exposure of RA W 264.7 to the indicated 
concentrations of either hemin or sodium arsenite, cytoplasmic extracts were treated with 
radiolabelled IRE probe and subjected to non-denaturing PAGE. The gels were dried and 
exposed to photographic film, to show the IRP activities (left panel). For the samples in 
the right panel, the lysates were treated with 2% ~-mercaptoethanol (~-ME) in order to 
demonstrate the total amount of IRP 1 present. B. IRP binding assay, as in A, in which 
the cells were pretreated with the shown concentrations of SnPP for 30 min prior to 
exposure to 5 J.!M hemin for 6 hr. C. Northen blot ofmRNA ex tracts from cells that had 
been treated for the indicated times in the presence of either 3 J.!M sodium arsenite or 5 
J.!M hernin. The blots were probed using either full-Iength ferritin heavy chain or actin 
cDNA (as a loading control). 
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Figure 4.5 Endogenous herne is not catabolized by induced HO-l. 
Left panel: 59Fe-hernin was added to cultured RA W 264.7 cells that been preincubated 
with or without 3 ~M sodium arsenite for 6 hr, to induce HO-l. After one hour, the cells 
were lysed and the herne and non-herne fractions evaluated according to Experimental 
Procedures. The data is presented as the fraction of total cell associated radioiron that 
rernained in herne. Right panel: Cells were grown in the presence of 1 /lM 59Fe2Tf. After 
3 days, half the sarnples were treated with sodium arsenite for 3 hr to induce HO-l. The 
percent age of cell associated 59Fe in herne was evaluated as described above. Error bars 
represent standard deviations. 
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effects ofheme oxygenase include the clearance ofheme, which in itse1f is cytotoxic (31-
33). In contrast, it has been shown that heme oxygenase overexpression or induction can 
confer cytoprotection in the absence of aberrant, extracorpuscular hemoproteins (5, 13, 
34-36).Additionally, the ability ofHO-l to be upregulated by a barrage ofnon-heme 
inducers strongly, though indirectly, implies a function for this enzyme in instances 
where extracellular heme is absent. Collective1y, the results of our study suggest that the 
heme catabolic activity ofHO-1 is irre1evant or subordinate in the enzyme's ability to 
protect cells against cellular stressors. 
Two recent studies by different groups have demonstrated that overexpression of 
HO, mutated to be devoid of catalytic activity (with respect to heme catabolism), will still 
confer protection against oxidative stress. Hori et al. transfected U937, macrophage-like 
cells, with catalytically inactive HO-l, finding that these cells were still able to withstand 
peroxide challenge (37). Doré's laboratory demonstrated a protective effect ofHO-2 
during heme challenge both in vitro (38) and in vivo (39). Interestingly, this ~oup . 
showed that catalytically inactive HO-2 will also protect cells against peroxide toxicity 
(38). Thus HO-2 possess an antioxidant function independent of its ability to degrade 
heme. It is like1y that the inducible form ofheme oxygnease, HO-l, functions similarly 
in tissues that do not express significant leve1s of HO-2 (i.e., most tissues besides testes 
and CNS); the potent cytoprotective effects of HO-l, may be, therefore, completely 
independent ofthe enzyme's ability to degrade heme. Altematively, it is possible that, 
rather than catabolyzing copious amounts ofheme to produce sufficient levels of 
potentially protective heme metabolites, HO-l plays its protective role by reducing the 
leve1s of a specific, pro-oxidant or pro-apoptotic hemoprotein. The re1ease of Fe2+ by the 
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heme oxygenase-catalyzed reaction cannot be ignored as a possible source of a potent 
pro-oxidant. Taille and coworkers have demonstrated that HO-l overexpression in RA W 
264.7 cells reduced cellular leve1s ofNAD(P)H oxidase, which generates most of the 
superoxide (02-) in these cells (40). Total hepatic cytochrome levels have also been 
documented in rats with chernically-induced (arsenic species) herne oxygenase (41,42). 
In contrast, the laboratory of Sinclair has shown that, although the leve1s of specific 
cytochromes P450 decrease with sodium arsenite-induction of HO-l, those effects are not 
the result ofincreased heme oxygenase activity (43). Recent studies have also implicated 
HO-l in mediating the anti-inflammatory effects of interleukin-l 0 (IL-l 0), indicating that 
HO-l may also exert its defensive properties via an as yet unexplored mechanism (44, 
45). Interestingly, Suttner et al. found significant migration ofHO-l into the nucleus of 
lung cells, which was associated with an increase in cell viability under hypoxia, 
suggesting that HO-l may affect the cellular stress response at a genetic leve1 (46). It is 
worthy to note that this study also found that there were no changes to reactive iron levels 
in HO-l overexpressing cells. 
In showing that the effect ofhernin on ferritin synthesis was through the liberation 
ofiron by HO-l, we confirm the original findings of Eisenstein et al. (14), who showed 
that chemical inhibition ofheme oxygenase prevented the induction of ferritin synthesis 
by 50 J.lM hernin. However, here we have used a significantly lower concentration of 
hemin (5 J.lM). In addition, we also dernonstrate that the IRE-IRP system is responsible 
for this effect ofhernin. Interestingly, while we were able to recover the IRE binding 
activity ofIRPl following hemin treatment by inhibiting heme oxygenase activity, IRP2 
was not recoverable. These results are consistent with recent evidence that hemin may 
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inhibit IRP2 activity independently of iron (47, 48), though the physiological relevance of 
this effect is questionable (49), especially in light of the fact that the pool of 
"uncommitted" herne in non-erythroid tissues is so minute. 
In conclusion, we have shown that, under normal conditions, there is virtually no heme 
substrate available for HO-l in macrophages or fibroblasts. The protection of tissues by 
this enzyme is therefore likely to be via an as of yet undescribed mechanism. 
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Chapter 
5 
General Discussion 
5.1 Discussion 
Iron is indispensable for life. This transition metal is at the focus of sorne of the 
most ancient and fundamental biological processes, inc1uding DNA production, cellular 
respiration, and amino acid synthesis. In addition to the trace levels of iron required for 
these pathways, vertebrates have an additional necessity for iron in the production and 
function ofhemoglobin; a comparatively gargantuan need for the metal. Ironically, the 
sarne chernical properties that instil iron with its biological utility impart an intrinsic 
toxicity to the metal. Thus, it is essential that the handling of iron be stringently 
controlled in order to maintain sufficient iron for normal function while simultaneously 
protecting the organism from the potential hazards of the metal. Regulatory mechanisms, 
most notably the IRE/IRP system, are in place so that individual cells are able to achieve 
proper iron homeostasis. Mechanisms to maintain the balance of systernic iron levels also 
exist, but have been difficult to characterize, as they require the coordination of iron 
handling by variou.s tissu.es throughout the body. Needless to say, deficient function in 
any contributor to this regulation will cause human disease. In order to understand how 
mammalian physiology is able to so delicately maintain proper systemic distribution of 
the metal, is it essential to fully appreciate the iron handling machinery per se. My 
doctoral research has shed light on the rernarkably efficient flow of iron through both the 
cells which are taking up the greatest arnount of iron and the cells which are releasing the 
greatest amounts of iron. 
In chapter two, we provide evidence that iron is transferred directly from an 
endosomal compartment to mitochondria. AlI of our experiments in that study were 
performed on reticulocytes, cells which are specialized for making large quantities of 
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hemoglobin. The utility of reticulocytes for such studies also cornes from the fact that 
they are easily obtainable, purely erythroid cells. Importantly, not only herne but also 
iron sulfur c1uster biogenesis occurs in the mitochondria (1). Since these two prosthetic 
groups represent the vast majority of functional iron in all tissue types, it is likely that this 
direct transfer paradigm is ubiquitous. However, it is important to note that there are a 
number of profound discrepancies between erythroid precursors and other tissues, 
inc1uding in proteins involved in iron metabolism (2). One important difference in 
erythroid tissues may be in their responses to iron: post-transcriptional regulation of Tf 
and Ft expression by iron appears to be lost in the later stages of erythroid differentiation 
(3). This observation is congruent with our hypothesis that iron delivered by transferrin 
in reticulocytes bypasses the cytosol, the location of the IRPs. Another obvious 
distinction of erythroid tissues is the unique form of ALA synthase (ALA-S2 or eALA-S), 
whose regulation is controlled by iron levels, rather than heme levels as for the 
"housekeeping" form of ALA-S. In addition~ whik it has been clearly documented that 
mutation of ALA-S2 can cause sideroblastic anernia, deficiency ofthe enzyme, by genetic 
ablation in mice, leads to cytoplasmic deposition of iron (4). Furthermore, an atternpt to 
rescue these mice by reintroduction of the ALA-S2 gene in below normallevels, led to 
formation of ringed sideroblasts (5). Therefore, the erythroid-specific form of ALA-S 
may play an important role in intracellular trafficking of iron to mitochondria. 
We have also shown that reticulocytes do not appear to endocytose any material 
other than transferrin. This fact along with the general specialized nature of these cells 
suggests that the vesicular trafficking pathway may be less complex than that of other 
cells. Kidney-derived cells are amongst the more commonly used models for examining 
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endocytosis. Undoubtedly, trafficking of materials through these both absorptive and 
secretary cells requires machinery that would be unnecessary in a cell whose 
overwhelming function is to produce hemoglobin. Future studies are required to 
understand what organellar markers are present on the different Tf-containing 
compartments (i.e., small and very motile, large and slow-moving, large and stationary) 
that we observe in reticulocytes. For exampIe, it has been shown that in CHO cells, TiR 
cycling proceeds according to the following pathway: 1) formation of a clathrin coated pit 
which matures into a vesicle and then an uncoated vesicle, 2) fusion or maturation of this 
primary endosome to a sorting endosome, 3) movement of the TiR to the endocytic 
recycling compartment, 4) fusion of an endocytic recycling compartment-derived vesicle 
with the plasma membrane (Figure 5.1) (6, 7). Along this route, various proteins, 
including Rab proteins, EEA1, and SNAREs, have been identified and assigned to these 
specifie endosomal structures (7). A location/role for Sec1511 (the protein which is 
affected in the hbd mouse) in this pathway is likely to soon emerge as ~ell. We have 
observe d, in reticulocytes, a tubular endosomal network that appears to be associated with 
mitochondria. Identification of endosomal proteins in this network will help to identif)r 
whether it is a form of the sorting endosome or the endocytic recycling compartment that 
has been observed eisewhere. Such experiments would also shed light on how this 
compartment may relate with the earlier and later phases of transferrin cycling in 
erythroid tissues, based on their complement of endocytosis-related proteins. 
Using microscopy, we were able to show that N-(6-aminohexyl)-5-chloro-l-
naphthalene-sulfonamide (W -7; specifie calmodulin inhibitor (8, 9)) prevents the 
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Figure 5.1 Transferrin Endocytosis. 
Endoéyticrecycling 
compartment 
pH 6.4-6.5 
• Lyso50mal enzyme 
• Fe3+ 
Following receptor binding, transferrin is intemalized via a c1athrin-coated pit, matures 
into a sorting endosome, gets transferred to the endocytic recyc1ing compartment, and is 
finally returned to the surface with its receptor. In this model, the iron is released in the 
sorting endosome, which has a lower pH than the endocytic recyc1ing compartment, 
however it is not known which compartment ultimately delivers the iron for use by the 
cell. 
Adapted [rom Maxfield and McGraw (7). 
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movement of transferrin within the reticulocyte. Our group has also shown, 
biochemically, that other inhibitors ofthe myosin motor will prevent the utilization of Tf-
borne iron by the cell. These inc1ude wortmanin (WT; inhibitor of myosin light chain 
kinase (10, Il », 1-5( -chloronaphthalene-l-sulfonyl)-Ih-hexahydro-l ,4-diazepine (ML-9; 
inhibitor ofmyosin light chain kinase (12, 13», and 2,3-butanedione monoxime (BDM; 
general myosin ATP inhibitor (14, 15» (16). In contrast, inhibitors ofmicrotubule 
function did not block the incorporation of endosomal iron into heme (16). Thus, we 
have shown that myosin motor activity is required not only for the movement of 
transferrin, but also for the transfer of vesicular iron to the mitochondria. Recent work by 
Mercer' s group has provided evidence in support of this role of myosin by showing that 
myosin Vb is required for holo-transferrin uptake (17). Using bafilomycin AI we were 
able to sufficiently label all ofthe endosomal compartments with 59Fe, as the distribution 
of fluorescent transferrin in cells that are treated with the inhibitor was identical to the 
untreated samples. Nevertheless, when W-7 was added, there was still a small amount of 
iron that was incorporated into heme. This could be due to a small fraction of 
internalized 59Fe2Tfwas present in mitochondria-associated endosomes and the iron 
therefore was able to be transferred to the mitochondria in the absence of endosomal 
movement. By passive observation, we have noticed that large, fluorescent structures 
appear to accumulate AG-Tfwith time, making larger endosomal structures visible after 
around 15 min of incubation at 37°C. We speculate that these structures are sorting 
endosomes that are able to somehow coordinate the flow of iron and transferrin through 
these cells. When cells that have been treated with AG-Tf for 30 min are washed and 
then exposed to unlabeled Fe2Tf, these compartments are the last to lose their 
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fluorescence (data nat shawn). Furthermore, we have done preliminary experiments that 
indicate a regulatory role of iron in the egress of apo-Tf, as FeSIH2 (an efficient, 
membrane permeable source of iron for use by the ceIl) prevents the release of a fraction 
of 1251_Tffrom cells that had been prelabeled with the iodinated protein (Appendix, 
Figure Al). Future study using fluorescent Tf in combination with immunolabeling for 
specific endosomal markers will elucidate the compartment that retains Fe2Tfwhen iron 
is continuously supplied to the cells. This will aid in understanding the mechanisms that 
indicate to a vesicle when it has unloaded its iron and should retum to a sorting 
compartment or the plasma membrane. FinaIly, if the presence of iron in the vesicle 
somehow initiates a signal to prevent the retum of that organelle towards the plasma 
membrane, it may be possible that the negative feedback effects ofheme on Fe2Tfuptake 
(18, 19) are actually mediated by iron release within one ofthese compartments. 
Unfortunately, the levels and possible roles ofheme oxygenase in erythroid tissues are 
totally unexplored. 
ln our analysis of iron and Tf trafficking in reticulocytes from hbd mice, we found 
the 1251_ Tfuptake curve to be almost identical to the inverse ofthe 1251_ Tfrelease curve. 
ln other words, the amount of Tf endocytosis matched that of Tf exocytosis. Given the 
known function ofSecl5 in the yeast exocyst (20, 21), one might expect the dwell time of 
Tfto be affected in reticulocytes from mutant mice. This balance ofuptake and release in 
spite of a defect in machinery that is very likely to be involved in the coordination of 
vesicular movementlfusion may suggest that there are mechanisms in place which 
maintain a balance of organellar and plasma membrane. Needless to say, hbd mi ce, 
though anemic, survive. Therefore, an equilibrium in transferrin uptake/release as weIl as 
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plasma membrane internalizationlexternalization must exist in their cells. It is tempting 
to speculate that there is a constant communication throughout the entire Tf cycle; that the 
cycle is a linear series in which any compromised component would translate throughout 
the cycle, thus becoming a bottleneck. An alternative would be a, possibly ubiquitous, 
intrinsic regulatory mechanism that senses and maintains the "size" of the intracellular 
compartments and the plasma membrane. If this were present, and the transferrin 
pathway followed a route similar to the scherne illustrated in Figure 5.1, then it may be 
interesting to measure ifthere is sorne Fe exocytosed by the mutant cells. This 
infonnation would help in understanding both the role of Sec 1511 and the regulation of 
intracellular iron trafficking. Finally, there is a very remote possibility that the 
reticulocytes are degrading Tf that cannot be exocytosed and somehow losing the 1251 
though a non-specifie pathway. This is unlikely for two reasons: 1) Tf-containing 
vesicles do not mature into lysosomal compartments; 2) There is no evidence that 
lysosomes are present in reticulocytes. 
The latest estimate for the number of genes in the human genome is 20,000-
25,000 (22). This number is generally surprisingly low to most medical researchers, who 
deem the number of genes proportional to the biological complexity of the organism. 
However, a growing number of proteins are being shown to have multiplicity of function. 
Perhaps the epitome of these proteins, in the context of iron metabolism, is IRP 1 which 
both binds RNA messages (Fe-S cluster absent) to regulate iron metabolism and has 
aconitase activity (Fe-S cluster present). Herne oxygenase has also ernerged as a protein 
with a "split personality". While the major role of this enzyme is to recycle iron from the 
herne of effete erythrocytes, is has been clearly established that herne oxygenase can also 
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protect cells from various modes of stress. Our study, presented in Chapter 4, suggests 
that this function of heme oxygenase is via an as of yet unexplained mechanism. 
Mice with an ablated HO-l gene survive. Surprisingly, these animaIs suffer from 
an unlikely dyad of tissue iron overload and hypoferremia (23). Whether the liberation of 
iron from heme is catalyzed by another HO isozyme or is non-enzymatic has not been 
determined. However, what is blatantly apparent is that, for sorne reason, the iron is not 
properly delivered to apo-Tf. This strongly suggests that HO-l plays sorne role in 
directing the movement of iron after its release from herne. Besides showing that ferritin 
synthesis is increased by iron released from heme via HO-l, we have observed in RA W 
264.7 macrophage-like cells, that a large proportion of 59Fe released frorn 59Fe-herne fed 
to the cells enters ferritin (Appendix, Figure A2). It must be pointed out here that 
immortalized celllines invariably take up excess iron and store most of the metal in 
ferritin under the artificial conditions of cell culture (24,25) (as exemplified by our 
exp~riments in which we grow RA W 264.7 cells in the presence of 59Fe_Tf for three days 
and observe over 90% ofthe cell associated iron in a non-herne fraction). Classical 
experiments by Finch's laboratory demonstrated decades ago that macrophages of the 
reticuloendothelial system return a significant fraction of erythrophagocytosed iron to 
plasma transferrin and store the rest of the iron in a more slowly released form (26). 
Their study also showed that the proportion of phagocytosed iron released by these cells 
is somehow increased to rneet erythropoietic dernand, under conditions that stimulate 
erythropoiesis. A flurry of recent papers has irnplicated the small, antirnicrobial peptide, 
hepcidin, in communicating the needs of the erythron and/or the status ofsystemic iron 
stores to macrophages of the RES and duodenal enterocytes (27). Nonetheless, it is still 
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uncertain precisely by what mechanism these specialized macrophages and enterocytes 
are able to maintain the Tf saturation level, which remains at around 30% even when 
erythropoiesis is increased up to 5 times the basallevel (26). 
At present, the route that heme takes to get to "microsomal" HO-l, following 
erythrophagocytosis is completely unknown. Because HO-l is an insoluble enzyme, 
tethered to ER membrane, it is likely that the phagosome, or a derivative of that organelle, 
fuses with ER or ER-derived structures (28). Subsequent to the release of iron via the 
HO-catalyzed reaction within this structure, again, the pathway followed by the metal is 
fully unknown. Based on the effects of an enigmatic signalling pathway that is likely to 
include hepcidin and the HFE protein, the macrophage becomes equipped to divide the 
phagocytosed iron appropriately between storage and release. In this vein it becomes 
crucial to understand the connection between ferritin and the regulation of cellular iron 
metabolism. In general, and what we observe in RA W 264.7 cells, excess cellular iron 
triggers ferritin synthesis. H~wever, we and others have also seen that increased ferritin 
(29, 30) or mitochondrial ferritin (31) synthesis will increase the amount of iron stored in 
ferritin and possibly deplete the cell of functional iron (31). However, ferroportin is 
likely to play an equally important role as ferritin in the regulation of RES macrophage 
iron release since it has been shown that the levels of this iron exporter are decreased 
following hepcidin binding, thus reducing macrophage iron release (27). Importantly, 
ferritin levels are observed to be reduced dramatically in cells transfected with ferroportin 
(32). Unfortunately, no definitive study has detennined the turnover rate of ferritin in 
tissues, making it difficult to speculate on the mechanisms governing how intracellular 
iron needs or, as in the case of RES macrophages, systemic iron demands may be satiated 
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by storage iron. If our observation that there is virtually no cytoplasmic labile iron in 
erythroid precursors extends to non-erythroid tissues and if the basal turnover rate of 
ferritin is not rapid, then we would expect that sorne signalling pathway is in place to 
stimulate ferritin degradation under iron depleted conditions. Thus, macrophage iron 
release entails a complex orchestration of the activities and/or levels of HO-l, ferritin, 
and ferroportin in response to extracellular eues. 
The biological paradox of requiring large amounts of iron while protecting the 
organism against the metal's toxicity has brought about the evolution of complex and 
intertwined iron handling pathways. The compromise of any single piece of the 
organism's iron metabolic machinery will almost invariably result in pathological 
consequences that affect multiple organismal systems. A considerable number ofhuman 
diseases are attributed to defects in sorne aspect or another of iron metabolism or the 
regulation thereof. Therefore, a comprehensive underst~nding of the iron metabolic 
pathways is pertinent to medical research. The original studies presented in my thesis 
exp and our comprehension of the two facets of iron metabolism that form the axis of 
organismal regulation of the metal: 1) iron acquisition by hemoglobin-producing cells and 
2) iron release by RES macrophages. The direct transfer of iron between the endosomal 
compartment and mitochondria is a paradigm that provides for the safe and efficient 
uptake of iron by cells. In this model, the iron atom would only have to undergo one 
redox step (the reduction oftransferrin-derived iron within the vesicle), before being 
inserted by ferrochelatase into the PPIX ring to form herne. Importantly, our depiction of 
this pathway does not entail a fusion of these organelles, which have vastly divergent 
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membrane compositions. For a fleeting instant, therefore, iron, having been released 
from its confinement in transferrin, exists in an "unbound" form within the endosome 
before it is transferred out ofthe organelle by DMTl (and handed offto a mitochondrial 
acceptor). Our studies strongly suggest that this is the single form of iron that is available 
for chelation. Hence, if our model proves to be ubiquitous, the design of therapies to 
alleviate pathologies associated with elevated catalytic iron must consider this trafficking 
model. 
Our finding that HO-l confers its protective effects through a mechanism that 
do es not apparently alter cellular heme/iron metabolism begs the question: what is the 
substrate for H 0-1 in non-phagocytic cells? As mentioned above, it is possible that H 0-1 
catalyzes a reaction that is completely remote from its ability to catabolize heme. 
Altematively, the enzyme may deplete the cell of a specific pro-oxidant or pro-apoptotic 
hemoprotein. For ex ample, cytochrome c release from mitochondria is an early stage 
event in apoptosis. Ifthe cytochrome c do es not contain a heme (i.e., apo-cytochr~me c), 
an active apoptosome cannot properly form and apoptosis will not ensue (33). In 
addition, cytochrome p450 2El is associated with increased oxidative stress in ethanol-
exposed hepatocytes (34). Since HO-l can degrade cytochrome heme (35,36), it is 
possible that specific degradation of the heme from these functional proteins is the 
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mechanism by which HO-l lends it protective property to cells. It is likely that the 
release ofa small amount ofiron from functional cytochromes' heme will not elicit 
significant alterations in cellular iron metabolism. Needless to say, this low herne 
catabolism is not expected to significantly elevate the levels ofherne metabolites that are 
touted as the effectors of oxidative stress protection by many laboratories. In any case, 
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understanding the precise mechanism ofHO-l protection is the key to developing 
strategies to treat conditions related to oxidative damage, including stroke, transplant 
rejection, Alzheimer disease, and Parkinson disease. The conclusions of our study that 
significant quantities ofheme are not being degraded in cells that are protected by HO-l 
must be taken into account in future studies striving to exploit the heme oxygenase 
system to combat such human diseases. 
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Figure A1. Effeet of iron supplementation on the release of 1251_ Tf from 
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Reticulocytes were incubated at 37°C for 15 min in the presence of 2 J.lM 1251_ Tf. After 
washing out the unbound 1251_ Tf, the cells were treated with or without Fe-SIH, a 
membrane permeant iron chelate that is able to deliver Fe for incorporation into heme. 
1251 appearance in the culture media was evaluated at each time point by gamma counting. 
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Figure A2. Distribution of 59Fe, liberated from 59Fe-hemin, in macrophages. 
Raw 264.7 cells were incubated in the presence of 40 /lM 59Fe-hemin (purified from 59Fe_ 
Tf treated reticulocytes). After 4 hr, the cells were washed in PBS and then lysed by 
mixing in a detergent-containing buffer (140 mM NaCI, 10 mM HEPES, 1.5% Triton X-
100, 1 mM PMSF; pH 7.4). The totallysates were subjected to polyacrylamide gel 
electrophoresis under non-denaturing conditions as previously described by Richardson et 
al. (37). The gel contained 1.5% Triton X-100 and a polyacrylamide gradient (3%-20%), 
so as to resolve low molecular weight molecules. Where shown, antibodies against Tf or 
Ft were added to the lysates , which were then incubated at 4°C for 30 min before loading 
into the gel. He, 59Fe-hemin; Ho, total cell homogenate; aTf, total homogenate + anti-Tf 
antibody; aFt, total homogenate + anti-Ft antibody. The arrowhead indicates the 59Fe_ 
hemin band, while the arrow indicates the ferritin band that was supershifted by the anti-
Ft antibody. Aggregates, likely to contain cell membrane material, that did not enter the 
running gel appears at the top of each lane containing homogenate. 
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The folJowing will confiml the safety and ethical conditions with regard to aU 
laboratories at tbe Lady Davis Institute for Medical Researcb of the Sir Mortimer B. 
Davis Jewish General Hospital. 
The Lady Davis Institute for Medical Research is a free-standing biomedical research 
institute attached to the Sir Mortimer B. Davis Jewish General Hospital, a major adult 
teaehing hospital affiliated with McGil1 University. There is appro"imately 110,000 sq. 
ft. of laboratory space occupied by over 65 independent investigators a11 of whom hold 
McGill University appointments in appropriate departments. At the presenttime we have 
.' ,approximately 100 graduate students and post-doctoral fellows registered with McGiII 
University. Total extemalfunding is in the range of$18 million (exclusive ofoverhead), 
. whîch is large by Canadian standards. 
Prof essor Andrew Mouland functions as Chair of our Health and Safety Committee, 
, while Professor John Hiscott, a virologist, heads the subcommittee of the Health and 
Safety Committee on Biohazards. 
Dr. Mouland affirms the safety program which addresses the question of radioactive 
material licence and Dr. Hiscott affi.rms the question of the use of recombinant DNA in 
the experiments. Dr. Lorraine Chalifour affirms the ethical use of animais. 
As a constituent part of McGill University the Institute follows and meets ail of the 
requirements of the McGill Laboratory Biosafety Manual. For those rare circumstances 
not covered by the McGill Laboratory Biosafety Manual we use the following as 
reference guidelines: 
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- Blasafety in Microbiological and Biomedical Laboratories, 3rd edition (1993)( 
Departnlent of Health· and Human Services (Public Health Service). Centers 
Control and Prevention, and the National Institutes of Health. U.S. Tnvern·mAltit· 
Office, Washington, D,C. 
o LaboratoryBiosafety Manual, Znd edition (1993). World Health Organization,Oeneya;:' .. ·· 
Switzerland. 
- Laboratory Biosafety Guidelines (1990). Medical Research COl.Ulcil of Càt1adli:arid 
Laboratory Centre for Disease Control, Health Protection Branch, Health Canada, 
Ottawa. Ctmada. 
- Labora/ory Safety, 2"d edition (1995). D.O.Fleming, J.H. Richardson, J.J. Tullis and D. 
VesIey, editors. ASM Press, Washington, D.C. 
o Guidelinesfor fiesearch Involving Recombinant DNA MoleCules (1996). U.S. 
DepartmeritofHealth and Muman Services, National Institutes ofHealth, Bethesda, M.D. 
Regularinspection of safety procedures are~Slb.~ùcte4"by theCanadiaii Nuc1ear Safety 
CommissÎon,(CNSC) (annuaI), ConteX SrivÎtonmtini" Qabo:i:atOry health and' safety 
consultants -'$Çveral times per year),the Sir Mortimer,.1J •. Davis Jewisb General Hospital 
Châjn'ltlillofInfection Control - Ore MarkMiUe~ (tnonthly),. tbe €atllldian Couucil ob 
Anirlllllèare (bi-annually), the McGillailima1CàreCommittee (monthly), as weil as by 
the Hospital Fire Marshal - Mr. Thomas Pr<lkos, and the City of Mo*,treal Fire 
Department (semi-llDnUally). . 
The Lady Davis Institute (LOn la1x>filtodesi!,lwhichthe research will be conducted are 
specially designéd' and equipped r6r's9ieutificresearch and are used solely for that 
purpose. Specialized faciIities are provideji,t()f the safe conduet of scientifie research, 
including but not Iimited to, wastedispOsârraèilities fol' .biohazatdous,. r8di:oactive and 
chenlical wastçsHl~eVèllc911t. .e., . . .. "'.' .... . al·l'~~ilities. An 
auto1Daticspiiilldêr:'sys~~,,,{watet) ;iUgt1dw:o,tti'e building. Fite. 
extingùisherilare located inseveràtlof: Il~xftobrs,asàre fll'e alarms. 
Fire dootS ~nd alarm pulls aremarke!l> .. .éJaboriJtories artcl tmimal rooms are. 
designed to have pressure di ,'" .,;)O~djlWé~.tar'Cas .. J:rll1'nce·. hoods are' 
monitored on a semi-annual bas1s;. , .. " ..'e~stto me.outside .. Biological saféty 
cabinets arecertified semi~annuaUY;'i~.;;d!<;:' .. '. . . . 
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